KR20060093072A - Cross-linked polymers of carbohydrates - Google Patents
Cross-linked polymers of carbohydrates Download PDFInfo
- Publication number
- KR20060093072A KR20060093072A KR1020060015801A KR20060015801A KR20060093072A KR 20060093072 A KR20060093072 A KR 20060093072A KR 1020060015801 A KR1020060015801 A KR 1020060015801A KR 20060015801 A KR20060015801 A KR 20060015801A KR 20060093072 A KR20060093072 A KR 20060093072A
- Authority
- KR
- South Korea
- Prior art keywords
- crosslinked
- skin
- gum
- acid dichloride
- carbohydrate component
- Prior art date
Links
- 150000001720 carbohydrates Chemical class 0.000 title claims abstract description 54
- 229920006037 cross link polymer Polymers 0.000 title claims abstract description 23
- 235000014633 carbohydrates Nutrition 0.000 title claims description 52
- 239000000203 mixture Substances 0.000 claims abstract description 43
- 239000002537 cosmetic Substances 0.000 claims abstract description 26
- 229920000642 polymer Polymers 0.000 claims abstract description 14
- 229920001282 polysaccharide Polymers 0.000 claims description 37
- 239000005017 polysaccharide Substances 0.000 claims description 36
- 150000004804 polysaccharides Chemical class 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 28
- 238000004132 cross linking Methods 0.000 claims description 24
- 229920001542 oligosaccharide Polymers 0.000 claims description 21
- 150000002482 oligosaccharides Chemical class 0.000 claims description 21
- 229920001285 xanthan gum Polymers 0.000 claims description 21
- 229920005862 polyol Polymers 0.000 claims description 19
- 150000003077 polyols Chemical class 0.000 claims description 19
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims description 18
- 239000008346 aqueous phase Substances 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 18
- 150000003138 primary alcohols Chemical group 0.000 claims description 18
- -1 polythioisocyanates Polymers 0.000 claims description 16
- 239000003431 cross linking reagent Substances 0.000 claims description 15
- 229920001525 carrageenan Polymers 0.000 claims description 14
- WMPOZLHMGVKUEJ-UHFFFAOYSA-N decanedioyl dichloride Chemical compound ClC(=O)CCCCCCCCC(Cl)=O WMPOZLHMGVKUEJ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000679 carrageenan Substances 0.000 claims description 13
- 229940113118 carrageenan Drugs 0.000 claims description 13
- LXEJRKJRKIFVNY-UHFFFAOYSA-N terephthaloyl chloride Chemical compound ClC(=O)C1=CC=C(C(Cl)=O)C=C1 LXEJRKJRKIFVNY-UHFFFAOYSA-N 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 12
- 235000010418 carrageenan Nutrition 0.000 claims description 11
- 229920002678 cellulose Polymers 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- 239000001913 cellulose Substances 0.000 claims description 10
- 125000000524 functional group Chemical group 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 235000010489 acacia gum Nutrition 0.000 claims description 9
- 235000010980 cellulose Nutrition 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 9
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 239000004971 Cross linker Substances 0.000 claims description 8
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 8
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 8
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- 229920001817 Agar Polymers 0.000 claims description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- 229920000084 Gum arabic Polymers 0.000 claims description 6
- 229930195725 Mannitol Natural products 0.000 claims description 6
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000205 acacia gum Substances 0.000 claims description 6
- 239000008272 agar Substances 0.000 claims description 6
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 6
- 239000000594 mannitol Substances 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 5
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims description 4
- 240000008886 Ceratonia siliqua Species 0.000 claims description 4
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
- 229920000926 Galactomannan Polymers 0.000 claims description 4
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 4
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 4
- 238000000855 fermentation Methods 0.000 claims description 4
- 230000004151 fermentation Effects 0.000 claims description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 4
- 229940029339 inulin Drugs 0.000 claims description 4
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 235000017709 saponins Nutrition 0.000 claims description 4
- 235000010413 sodium alginate Nutrition 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 230000037303 wrinkles Effects 0.000 claims description 4
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 229920002581 Glucomannan Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 229920001744 Polyaldehyde Polymers 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 150000001805 chlorine compounds Chemical class 0.000 claims description 3
- 229940046240 glucomannan Drugs 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000012071 phase Substances 0.000 claims description 3
- 229920001228 polyisocyanate Polymers 0.000 claims description 3
- 239000005056 polyisocyanate Substances 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 claims description 2
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 claims description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 2
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 claims description 2
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 2
- 229920000945 Amylopectin Polymers 0.000 claims description 2
- 229920000856 Amylose Polymers 0.000 claims description 2
- 244000106483 Anogeissus latifolia Species 0.000 claims description 2
- 235000011514 Anogeissus latifolia Nutrition 0.000 claims description 2
- 240000005209 Canarium indicum Species 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 2
- 244000303965 Cyamopsis psoralioides Species 0.000 claims description 2
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-CBPJZXOFSA-N D-Gulose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-CBPJZXOFSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 2
- HAIWUXASLYEWLM-UHFFFAOYSA-N D-manno-Heptulose Natural products OCC1OC(O)(CO)C(O)C(O)C1O HAIWUXASLYEWLM-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 239000004386 Erythritol Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- MUPFEKGTMRGPLJ-OBAJZVCXSA-N Gentianose Natural products O(C[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@H](O)[C@@H](CO)O2)O1)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-OBAJZVCXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000001922 Gum ghatti Substances 0.000 claims description 2
- 229920000569 Gum karaya Polymers 0.000 claims description 2
- 229920002752 Konjac Polymers 0.000 claims description 2
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 claims description 2
- HSNZZMHEPUFJNZ-UHFFFAOYSA-N L-galacto-2-Heptulose Natural products OCC(O)C(O)C(O)C(O)C(=O)CO HSNZZMHEPUFJNZ-UHFFFAOYSA-N 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 241000206572 Rhodophyta Species 0.000 claims description 2
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 claims description 2
- 240000005481 Salvia hispanica Species 0.000 claims description 2
- 235000001498 Salvia hispanica Nutrition 0.000 claims description 2
- HAIWUXASLYEWLM-AZEWMMITSA-N Sedoheptulose Natural products OC[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@](O)(CO)O1 HAIWUXASLYEWLM-AZEWMMITSA-N 0.000 claims description 2
- 229920001800 Shellac Polymers 0.000 claims description 2
- 244000061456 Solanum tuberosum Species 0.000 claims description 2
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- FLUADVWHMHPUCG-OVEXVZGPSA-N Verbascose Natural products O(C[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](OC[C@@H]2[C@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]3(CO)[C@H](O)[C@@H](O)[C@@H](CO)O3)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 FLUADVWHMHPUCG-OVEXVZGPSA-N 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- 239000000305 astragalus gummifer gum Substances 0.000 claims description 2
- QLTSDROPCWIKKY-PMCTYKHCSA-N beta-D-glucosaminyl-(1->4)-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1 QLTSDROPCWIKKY-PMCTYKHCSA-N 0.000 claims description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 2
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 claims description 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 claims description 2
- 235000014167 chia Nutrition 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 150000002016 disaccharides Chemical class 0.000 claims description 2
- 239000004862 elemi Substances 0.000 claims description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 2
- 235000019414 erythritol Nutrition 0.000 claims description 2
- 229940009714 erythritol Drugs 0.000 claims description 2
- UQPHVQVXLPRNCX-UHFFFAOYSA-N erythrulose Chemical compound OCC(O)C(=O)CO UQPHVQVXLPRNCX-UHFFFAOYSA-N 0.000 claims description 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 claims description 2
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 claims description 2
- 229930182830 galactose Natural products 0.000 claims description 2
- MUPFEKGTMRGPLJ-WSCXOGSTSA-N gentianose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-WSCXOGSTSA-N 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 229950006191 gluconic acid Drugs 0.000 claims description 2
- 235000012209 glucono delta-lactone Nutrition 0.000 claims description 2
- 229960003681 gluconolactone Drugs 0.000 claims description 2
- 229960002442 glucosamine Drugs 0.000 claims description 2
- 229960002849 glucosamine sulfate Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229940029575 guanosine Drugs 0.000 claims description 2
- 235000019314 gum ghatti Nutrition 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229960000367 inositol Drugs 0.000 claims description 2
- 235000010494 karaya gum Nutrition 0.000 claims description 2
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 claims description 2
- 239000000252 konjac Substances 0.000 claims description 2
- 235000019823 konjac gum Nutrition 0.000 claims description 2
- 239000000832 lactitol Substances 0.000 claims description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 2
- 235000010448 lactitol Nutrition 0.000 claims description 2
- 229960003451 lactitol Drugs 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 claims description 2
- 229920003087 methylethyl cellulose Polymers 0.000 claims description 2
- 150000002772 monosaccharides Chemical class 0.000 claims description 2
- QIGJYVCQYDKYDW-NSYYTRPSSA-N nigerose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-NSYYTRPSSA-N 0.000 claims description 2
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 239000002151 riboflavin Substances 0.000 claims description 2
- 235000019192 riboflavin Nutrition 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- HSNZZMHEPUFJNZ-SHUUEZRQSA-N sedoheptulose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO HSNZZMHEPUFJNZ-SHUUEZRQSA-N 0.000 claims description 2
- 239000004208 shellac Substances 0.000 claims description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 2
- 229940113147 shellac Drugs 0.000 claims description 2
- 235000013874 shellac Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 229960002385 streptomycin sulfate Drugs 0.000 claims description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 2
- 229940045145 uridine Drugs 0.000 claims description 2
- FLUADVWHMHPUCG-SWPIJASHSA-N verbascose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)O3)O)O2)O)O1 FLUADVWHMHPUCG-SWPIJASHSA-N 0.000 claims description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 239000001879 Curdlan Substances 0.000 claims 1
- 229920002558 Curdlan Polymers 0.000 claims 1
- ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 claims 1
- 239000001116 FEMA 4028 Substances 0.000 claims 1
- 244000098338 Triticum aestivum Species 0.000 claims 1
- DRQXUCVJDCRJDB-UHFFFAOYSA-N Turanose Natural products OC1C(CO)OC(O)(CO)C1OC1C(O)C(O)C(O)C(CO)O1 DRQXUCVJDCRJDB-UHFFFAOYSA-N 0.000 claims 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims 1
- 229960004853 betadex Drugs 0.000 claims 1
- 235000019316 curdlan Nutrition 0.000 claims 1
- 229940078035 curdlan Drugs 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims 1
- 235000010492 gellan gum Nutrition 0.000 claims 1
- 239000000216 gellan gum Substances 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 150000003396 sophoroses Chemical class 0.000 claims 1
- RULSWEULPANCDV-PIXUTMIVSA-N turanose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](C(=O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RULSWEULPANCDV-PIXUTMIVSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 51
- 238000002360 preparation method Methods 0.000 abstract description 26
- 125000000075 primary alcohol group Chemical group 0.000 abstract 2
- 239000000243 solution Substances 0.000 description 38
- 239000007864 aqueous solution Substances 0.000 description 23
- 239000000047 product Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 238000006116 polymerization reaction Methods 0.000 description 13
- 238000003756 stirring Methods 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 125000003158 alcohol group Chemical group 0.000 description 4
- 150000008064 anhydrides Chemical class 0.000 description 4
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- BITMAWRCWSHCRW-PFQJHCPISA-N Raffinose Pentahydrate Chemical compound O.O.O.O.O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 BITMAWRCWSHCRW-PFQJHCPISA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- GTDPSWPPOUPBNX-UHFFFAOYSA-N ac1mqpva Chemical compound CC12C(=O)OC(=O)C1(C)C1(C)C2(C)C(=O)OC1=O GTDPSWPPOUPBNX-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001719 carbohydrate derivatives Chemical class 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000007797 corrosion Effects 0.000 description 2
- 238000005260 corrosion Methods 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 229940120503 dihydroxyacetone Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 229940119170 jojoba wax Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 231100000344 non-irritating Toxicity 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid group Chemical group C(C=1C(C(=O)O)=CC=CC1)(=O)O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229920005903 polyol mixture Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- JHRHFFULXFLTPE-UHFFFAOYSA-N 1-propan-2-yloxyhexadecan-2-ol Chemical compound CCCCCCCCCCCCCCC(O)COC(C)C JHRHFFULXFLTPE-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- BJRXGOFKVBOFCO-UHFFFAOYSA-N 2-hydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(C)O BJRXGOFKVBOFCO-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 240000009226 Corylus americana Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 108700037001 Lactoperoxidases Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101800000789 Protease-polymerase p70 Proteins 0.000 description 1
- 101800000786 Protease-polymerase p76 Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HIWPGCMGAMJNRG-ACCAVRKYSA-N Sophorose Natural products O([C@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HIWPGCMGAMJNRG-ACCAVRKYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000019888 Vivapur Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- FYXKZNLBZKRYSS-UHFFFAOYSA-N benzene-1,2-dicarbonyl chloride Chemical compound ClC(=O)C1=CC=CC=C1C(Cl)=O FYXKZNLBZKRYSS-UHFFFAOYSA-N 0.000 description 1
- HIWPGCMGAMJNRG-UHFFFAOYSA-N beta-sophorose Natural products OC1C(O)C(CO)OC(O)C1OC1C(O)C(O)C(O)C(CO)O1 HIWPGCMGAMJNRG-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- IRXBNHGNHKNOJI-UHFFFAOYSA-N butanedioyl dichloride Chemical compound ClC(=O)CCC(Cl)=O IRXBNHGNHKNOJI-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 125000006159 dianhydride group Chemical group 0.000 description 1
- 229940100539 dibutyl adipate Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 229940060384 isostearyl isostearate Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- QENHCSSJTJWZAL-UHFFFAOYSA-N magnesium sulfide Chemical compound [Mg+2].[S-2] QENHCSSJTJWZAL-UHFFFAOYSA-N 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- HGEVGSTXQGZPCL-UHFFFAOYSA-N nonanedioyl dichloride Chemical compound ClC(=O)CCCCCCCC(Cl)=O HGEVGSTXQGZPCL-UHFFFAOYSA-N 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000059 polyethylene glycol stearate Polymers 0.000 description 1
- 239000004848 polyfunctional curative Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- PZDOWFGHCNHPQD-VNNZMYODSA-N sophorose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PZDOWFGHCNHPQD-VNNZMYODSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H1/00—Apparatus for passive exercising; Vibrating apparatus; Chiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
- A61H1/02—Stretching or bending or torsioning apparatus for exercising
- A61H1/0214—Stretching or bending or torsioning apparatus for exercising by rotating cycling movement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H1/00—Apparatus for passive exercising; Vibrating apparatus; Chiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
- A61H1/008—Apparatus for applying pressure or blows almost perpendicular to the body or limb axis, e.g. chiropractic devices for repositioning vertebrae, correcting deformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H1/00—Apparatus for passive exercising; Vibrating apparatus; Chiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
- A61H1/02—Stretching or bending or torsioning apparatus for exercising
- A61H1/0292—Stretching or bending or torsioning apparatus for exercising for the spinal column
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/732—Starch; Amylose; Amylopectin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/927—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of insects, e.g. shellac
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
- C08B15/005—Crosslinking of cellulose derivatives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
- C08B15/10—Crosslinking of cellulose
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/003—Crosslinking of starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B31/00—Preparation of derivatives of starch
- C08B31/003—Crosslinking of starch
- C08B31/006—Crosslinking of derivatives of starch
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0033—Xanthan, i.e. D-glucose, D-mannose and D-glucuronic acid units, saubstituted with acetate and pyruvate, with a main chain of (beta-1,4)-D-glucose units; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0036—Galactans; Derivatives thereof
- C08B37/0042—Carragenan or carragen, i.e. D-galactose and 3,6-anhydro-D-galactose, both partially sulfated, e.g. from red algae Chondrus crispus or Gigantia stellata; kappa-Carragenan; iota-Carragenan; lambda-Carragenan; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0051—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Fructofuranans, e.g. beta-2,6-D-fructofuranan, i.e. levan; Derivatives thereof
- C08B37/0054—Inulin, i.e. beta-2,1-D-fructofuranan; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
- C08B37/0093—Locust bean gum, i.e. carob bean gum, with (beta-1,4)-D-mannose units in the main chain branched with D-galactose units in (alpha-1,6), e.g. from the seeds of carob tree or Ceratonia siliqua; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/12—Driving means
- A61H2201/1207—Driving means with electric or magnetic drive
- A61H2201/1215—Rotary drive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/14—Special force transmission means, i.e. between the driving means and the interface with the user
- A61H2201/1436—Special crank assembly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/14—Special force transmission means, i.e. between the driving means and the interface with the user
- A61H2201/1463—Special speed variation means, i.e. speed reducer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/04—Preparations containing skin colorants, e.g. pigments for lips
- A61Q1/06—Lipsticks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Emergency Medicine (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cosmetics (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Saccharide Compounds (AREA)
Abstract
본 발명에는 하나 이상의 일차 알콜 관능기를 포함하는 하나 이상의 탄수화물 성분을 갖는 가교된 중합체가 개시되어 있다. 상기 중합체는 피부에 도포하여 텐싱 및(또는) 토닝 효과를 얻고자 하는 조성물의 제조에 사용될 수 있다.The present invention discloses crosslinked polymers having at least one carbohydrate component comprising at least one primary alcohol function. The polymer may be used in the preparation of a composition which is intended to be applied to the skin to obtain a tensioning and / or toning effect.
가교된 중합체, 일차 알콜 관능기, 탄수화물 성분, 화장료 조성물 Crosslinked polymers, primary alcohol functional groups, carbohydrate components, cosmetic compositions
Description
[특허문헌 1] WO 94/18944[Patent Document 1] WO 94/18944
[특허문헌 2] 프랑스 특허 제2,766,090호 (미국 특허 제5,912,016호에 상응함)[Patent Document 2] French Patent No. 2,766,090 (corresponds to US Patent No. 5,912,016)
[특허문헌 3] 프랑스 특허 제2,780,901호 (미국 특허 제6,197,757호에 상응함)[Patent Document 3] French Patent No. 2,780,901 (corresponds to US Patent No. 6,197,757)
[특허문헌 4] WO 03/040216 A1[Patent Document 4] WO 03/040216 A1
본 발명은 다양한 단백질 또는 펩티드 물질에 기재하여 상기 물질로 인한 알레르기의 문제점을 회피하는, 텐싱(tensing) 효과를 갖는 활성 성분의 제조에 관한 것이다. 본 발명은 또한 탄수화물의 가교된 중합체의 제조에 관한 것이다.The present invention relates to the preparation of active ingredients having a tensioning effect, based on various protein or peptide materials, avoiding the problem of allergies due to the materials. The invention also relates to the preparation of crosslinked polymers of carbohydrates.
화장료 제제는 매우 종종 특징적인 텐싱 효과가 유도되도록 하는 물질을 함유한다. 이러한 효과로 인해 특히 소비자에 의해 유의하게 감지되는 감각적인 효과에 의한 화장료 제제의 효능성의 인지의 개선이 가능하다.Cosmetic preparations very often contain substances which allow a characteristic tensioning effect to be induced. This effect makes it possible to improve the perception of the efficacy of cosmetic preparations, in particular by the sensory effects that are significantly perceived by the consumer.
또한, 상기 텐싱 효과는 눈가, 목, 목선 또는 손 형태의 제제에 사용되어 한 편으로는 피부 주름의 즉각적이지만 일시적인 감소를 가능하게 하며, 다른 한편으로는 피부의 팽팽함을 가능하게 한다.In addition, the tensioning effect is used in preparations in the form of eyes, neck, neckline or hands to allow an immediate but temporary reduction in skin wrinkles on the one hand and to tighten the skin on the other hand.
상기 특성으로 가장 잘 알려진 물질 중에서, 소 혈청 알부민 또는 콜라겐은 과거에 가장 빈번히 사용되어 왔던 분자였다. 보다 최근에는, 상기 활성용으로 개발된 물질은 식물 기원의 물질을 향해 바뀌고 있으며, 식물성 단백질이 특히 상기 활성을 위해 폭넓게 사용되어 왔다.Among the substances best known for this property, bovine serum albumin or collagen was the molecule most frequently used in the past. More recently, materials developed for this activity are turning towards materials of plant origin, and vegetable proteins have been widely used, particularly for the activity.
즉, 예를 들어 곡류 또는 콩과 식물의 식물성 알부민 분획은 소 혈청 알부민과의 유사성에 대한 특히 흥미있는 특허의 대상이었다 (WO 94/18944). 유사하게, 이관능화제를 사용한 식물성 단백질의 중합이 다양한 화장료 용도에 대해 기재되었다. 프랑스 특허 제2,766,090호 (미국 특허 제5,912,016호에 상응함), 및 프랑스 특허 제2,780,901호 (미국 특허 제6,197,757호에 상응함) 참조. 또한, 식물성 단백질의 가수분해된 분획의 중합에 의해 제조된 물질이 화장료에서의 텐싱 효과용으로 기재되었고, 사용되었다 (WO 03/040216 A1). That is, for example, the vegetable albumin fraction of cereals or legumes has been the subject of a particularly interesting patent for similarity with bovine serum albumin (WO 94/18944). Similarly, the polymerization of vegetable proteins with difunctional agents has been described for various cosmetic applications. See French Patent 2,766,090 (corresponds to US Pat. No. 5,912,016), and French Patent 2,780,901 (corresponds to US Pat. No. 6,197,757). In addition, materials prepared by the polymerization of hydrolyzed fractions of vegetable proteins have been described and used for tensioning effects in cosmetics (WO 03/040216 A1).
그러나, 화장료에서의 단백질의 사용은 이들이 다양한 농도에서 면역 반응, 심지어 총체적 과민성을 초래할 수 있는 알레르기를 유도할 수 있기 때문에 문제가 된다. 밀, 견과류, 개암, 땅콩, 우유 기원의 단백질은 이러한 면역 반응을 유발하는 것으로서 당업자에게 널리 공지된 상기 단백질의 소수 예이다.However, the use of proteins in cosmetics is problematic because they can induce allergic reactions at various concentrations which can lead to immune responses and even overall hypersensitivity. Proteins of wheat, nut, hazelnut, peanut, milk origin are a few examples of such proteins that are well known to those skilled in the art as eliciting this immune response.
앞으로, 화장료에서 단백질과 같은 피부에 자극적인 화합물의 사용은 법률 때문에 제한되거나 금지될 수 있음을 고려할 필요가 있다.In the future, it is necessary to take into account that the use of skin-irritating compounds such as proteins in cosmetics may be restricted or prohibited by law.
종래 기술에는 당업자가 텐싱 효과용으로 화장료 또는 약제에 사용될 수 있 는 특정 화합물이 또한 종종 자극을 유발할 수 있다는 문제점을 경감시킬 수 있도록 하는 특정 용액이 기재되어 있지 않다. The prior art does not describe specific solutions that allow one of ordinary skill in the art to alleviate the problem that certain compounds that can be used in cosmetics or medicaments for the tensioning effect can also often cause irritation.
본 발명이 특히 목적하는 신규한 기술적 문제점의 해결은, 임의의 확인가능한 알레르기 반응을 유발하지 않고도 사용자에 의해 인지가능한 방식으로 피부 표면에서 텐싱 및(또는) 토닝 효과를 얻을 수 있는 화합물을 제공하는 것으로 이루어진다.The solution to the novel technical problem particularly aimed at by the present invention is to provide compounds which can obtain a tensioning and / or toning effect at the skin surface in a perceptible manner by the user without causing any identifiable allergic reaction. Is done.
본 발명이 목적하는 기술적 문제점의 해결은, 재생성 생물학적 물질로부터 기원하며, 동물계 뿐만 아니라 식물계에도 존재할 수 있고, 또한 미생물 발효에 의해 제조될 수도 있는, 바람직하게는 우수한 생체적합성, 완전한 생체분해성, 완전한 동화, 완전한 무해성을 갖는 출발 물질에 기재한 토닝 용액을 제공하는 것으로 이루어진다.The solution of the technical problem for which the present invention aims is preferably of good biocompatibility, complete biodegradability, complete assimilation, originating from renewable biological materials, which may be present in animal as well as plant systems, and may also be prepared by microbial fermentation. And providing a toning solution described in the starting material which is completely harmless.
본 발명이 목적하는 기술적 문제점의 해결은, 또한 상기 언급된 기술적 문제점의 해결을 가능하게 하는 화합물의 신규한 제조 방법을 제공하는 것으로 이루어진다.The solution of the technical problem aimed at by the present invention also consists in providing a novel process for the preparation of the compound which makes it possible to solve the above mentioned technical problem.
상기 기술적 문제점 전부는 본 발명에 의해 최초로 만족스럽고, 저렴하며, 공업적 규모로, 특히 화장료적 규모로 사용될 수 있는 방식으로 해결된다.All of these technical problems are solved by the present invention in such a way that they can be used for the first time, satisfactorily, inexpensively, on an industrial scale, in particular on a cosmetic scale.
놀랍게도 본 발명자들은 탄수화물 또는 탄수화물 유도체 1종 이상의 중합체가 인간의 피부와 같은 피부 조직의 텐싱 및(또는) 토닝 효과를 얻게 할 수 있음을 밝혀내었다.Surprisingly, the inventors have found that one or more polymers of carbohydrates or carbohydrate derivatives can achieve tensioning and / or toning effects of skin tissue such as human skin.
따라서, 제1 측면에 따르면, 본 발명은 하나 이상의 일차 알콜 관능기를 포함하는 1종 이상의 탄수화물의 가교된 중합체에 관한 것이며, 특히 하기 정의된 방법에 따르면 수득가능한 가교된 중합체에 관한 것이다. 상기 중합체에는 하나 이상의 일차 알콜 관능기를 포함하는 1종 이상의 탄수화물의 중합체 중 캡슐 또는 스피어의 형태, 특히 마이크로캡슐 또는 마이크로스피어의 형태, 또는 나노캡슐 또는 나노스피어의 형태는 제외된다.Thus, according to a first aspect, the present invention relates to a crosslinked polymer of at least one carbohydrate comprising at least one primary alcohol function, in particular to a crosslinked polymer obtainable according to the method defined below. The polymer excludes in the form of capsules or spheres, in particular in the form of microcapsules or microspheres, or in the form of nanocapsules or nanospheres, in polymers of at least one carbohydrate comprising at least one primary alcohol function.
제2 측면에 따르면, 본 발명은 상기 정의된 바와 같은 가교된 중합체를 포함하는 화장료 조성물, 피부-제약 조성물 및(또는) 제약 조성물에 관한 것이다.According to a second aspect, the present invention relates to a cosmetic composition, a skin-pharmaceutical composition and / or a pharmaceutical composition comprising a crosslinked polymer as defined above.
또한, 제3 측면에 따르면, 본 발명은 대상체의 피부 조직에 도포하여 상기 조직에서 텐싱 및(또는) 토닝 효과를 얻고자 하는 조성물의 제조를 위한, 상기 정의된 바와 같은 가교된 중합체의 용도에 관한 것이다.According to a third aspect, the present invention also relates to the use of a crosslinked polymer as defined above for the preparation of a composition which is applied to skin tissue of a subject to obtain a tensioning and / or toning effect in said tissue. will be.
본원에 사용된 "탄수화물"이라는 용어는 하나 이상의 일차 알콜 관능기를 포함하는 탄수화물 및 탄수화물 유도체를 의미한다.As used herein, the term "carbohydrate" refers to carbohydrates and carbohydrate derivatives comprising one or more primary alcohol functional groups.
본 발명의 내용에서, 텐싱 및(또는) 토닝 효과는 특히 지원자의 의견의 관점에서, 피부 조도의 측정으로부터 및(또는) 비-가교된 탄수화물의 수용액과 비교시 가교된 탄수화물의 수용액의 점도로부터 측정된다. In the context of the present invention, the tensioning and / or toning effect is determined from the viscosity of the aqueous solution of crosslinked carbohydrates, in particular from the perspective of the applicant's opinion, from the measurement of skin roughness and / or compared to the aqueous solution of non-crosslinked carbohydrates. do.
한 가지 변형법에 따르면, 본 발명은 대상체의 피부 조직에 도포하여 상기 조직의 주름 및(또는) 잔주름의 감소를 얻고자 하는 조성물의 제조를 위한, 가교된 중합체의 용도에 관한 것이다.According to one variant, the invention relates to the use of a crosslinked polymer for the preparation of a composition which is applied to skin tissue of a subject to obtain a reduction in wrinkles and / or fine lines of said tissue.
또다른 변형법에 따르면, 본 발명은 대상체의 피부 조직에 도포하여 상기 조직의 생물기계적 특성을 개선시키고자 하는 조성물의 제조를 위한, 가교된 중합체의 용도에 관한 것이다.According to another variant, the present invention relates to the use of a crosslinked polymer for the preparation of a composition intended to be applied to skin tissue of a subject to improve the biomechanical properties of the tissue.
유리하게는, 상기 조성물은 안면의 적어도 한 부분, 특히 눈의 윤곽선, 목, 손, 목선 및(또는) 가슴에 도포하고자 하는 화장료 조성물, 피부-제약 조성물 또는 제약 조성물이다.Advantageously, the composition is a cosmetic composition, skin-pharmaceutical composition or pharmaceutical composition intended to be applied to at least one part of the face, especially the contours of the eye, neck, hands, neckline and / or chest.
본 발명으로부터 기원한 생성물은 이를 함유하는 조성물을 피부에 도포할 때 토닝 효과를 갖는다. 본 발명으로부터 기원한 생성물은 이러한 조성물을 피부에 도포할 때 임의의 확인가능한 알레르기 형성 효과를 갖지 않는다.The product derived from the present invention has a toning effect when applying a composition containing the same to the skin. The products derived from the present invention do not have any appreciable allergic effect when applying such compositions to the skin.
본 발명의 생성물은 피부의 표면에 흡착되어 부드럽고 연속적인 탄성 필름을 형성한다. 따라서, 이렇게 중합된 탄수화물, 특히 다당류, 올리고당류 및(또는) 폴리올의 필모제닉(filmogenic) 특성, 텐싱 및 가소화 특성은 특히 흥미롭다.The product of the present invention is adsorbed on the surface of the skin to form a smooth and continuous elastic film. Thus, the filmogenic, tensioning and plasticizing properties of such polymerized carbohydrates, in particular polysaccharides, oligosaccharides and / or polyols, are of particular interest.
유리하게는, 본 발명의 생성물은 따라서 필모제닉 및(또는) 가소화 특성을 갖는다.Advantageously, the product of the present invention thus has filmogenic and / or plasticization properties.
바람직하게는, 탄수화물은 다당류, 올리고당류, 폴리올, 및 이들의 혼합물 중 어느 하나로부터 선택된다.Preferably, the carbohydrate is selected from any of polysaccharides, oligosaccharides, polyols, and mixtures thereof.
제4 측면에 따르면, 본 발명은 상기 정의된 바와 같은 조성물을 국소 도포하는 것을 포함하는 미용 관리 방법에 관한 것이다.According to a fourth aspect, the present invention relates to a cosmetic care method comprising topically applying a composition as defined above.
본 출원인은 다당류 또는 올리고당류의 중합 방법에 대해 알고 있다 (콜렉티카(COLETICA), 프랑스 특허 제2,688,422호, 미국 특허 제5,562,924호). 그러나, 상기 방법은 마이크로캡슐 및 마이크로스피어의 제조용 에멀젼에서의 계면 중합 방법이다. 따라서, 상기 방법으로는 스피어 및(또는) 캡슐의 형태, 특히 마이크로캡슐 또는 마이크로스피어의 형태 이외의 고분자량 탄수화물 중합체를 수득할 수 없다.Applicants are aware of methods for the polymerization of polysaccharides or oligosaccharides (COLETICA, French Patent No. 2,688,422, US Patent No. 5,562,924). However, this method is an interfacial polymerization method in emulsions for preparing microcapsules and microspheres. Thus, it is not possible to obtain high molecular weight carbohydrate polymers other than in the form of spheres and / or capsules, in particular in the form of microcapsules or microspheres.
따라서, 제5 측면에 따르면, 본 발명에는 균질한 수성상에서 탄수화물의 일차 알콜 관능기와 가교제의 반응성 관능기 사이의 가교 반응으로 1종 이상의 탄수화물의 가교된 중합체를 수득하는 것을 포함하는, 가교된 중합체의 제조 방법이 기재되어 있다. Thus, according to a fifth aspect, the present invention comprises preparing a crosslinked polymer of at least one carbohydrate by crosslinking reaction between a primary alcohol function of a carbohydrate and a reactive functional group of a crosslinker in a homogeneous aqueous phase. The method is described.
바람직하게는, 탄수화물은 다당류, 올리고당류, 폴리올, 및 이들의 혼합물 중 임의의 하나로부터 선택된다.Preferably, the carbohydrate is selected from any one of polysaccharides, oligosaccharides, polyols, and mixtures thereof.
제1 실시양태에서, 탄수화물, 특히 폴리올 및(또는) 올리고당류는 분자량이 150 g/mol (이하의 내용에서, g/mol 또는 달톤 또는 Da로 표시함) 이상, 바람직하게는 2,000 Da 이상이다.In a first embodiment, the carbohydrates, in particular polyols and / or oligosaccharides, have a molecular weight of at least 150 g / mol (denoted in g / mol or Dalton or Da in the following), preferably at least 2,000 Da.
유리하게는, 상기 제1 실시양태에서, 가교제에 대한 탄수화물, 특히 폴리올 및(또는) 올리고당류의 몰비는 0.1 초과, 바람직하게는 1 이상이다.Advantageously, in this first embodiment, the molar ratio of carbohydrates, in particular polyols and / or oligosaccharides, to the crosslinking agent is greater than 0.1, preferably at least 1.
제2 실시양태에서, 탄수화물, 특히 다당류의 분쟈량은 50,000 Da 이상, 바람직하게는 100,000 Da 이상, 보다 바람직하게는 300,000 Da 이상이다. 이 경우, 가수분해는, 중합 반응이 특히 가용성 중합체를 생성할 수 있도록, 가교 반응 전에 수행될 수 있다. 탄수화물의 가수분해 방법은 당업자에게 공지되어 있다.In a second embodiment, the molecular weight of carbohydrates, in particular polysaccharides, is at least 50,000 Da, preferably at least 100,000 Da, more preferably at least 300,000 Da. In this case, hydrolysis can be carried out before the crosslinking reaction so that the polymerization reaction can in particular produce a soluble polymer. Methods of hydrolysis of carbohydrates are known to those skilled in the art.
유리하게는, 상기 제2 실시양태에서, 가교제에 대한 탄수화물, 특히 다당류 의 몰비는 0.1 미만, 바람직하게는 0.01 미만이다.Advantageously, in this second embodiment, the molar ratio of carbohydrates, in particular polysaccharides, to the crosslinking agent is less than 0.1, preferably less than 0.01.
유리하게는, 다당류는 디오시딕(diosidic) 잔기당 일차 알콜 관능기 0.5 내지 4개를 포함한다.Advantageously, the polysaccharide comprises 0.5 to 4 primary alcohol functional groups per diosidic residue.
유리하게는, 반응 전, 탄수화물은 국소 경로를 통해 허용되는 부형제, 특히 화장료적으로 또는 피부과적으로 허용되는 부형제와의 혼합물이다.Advantageously, prior to the reaction, the carbohydrate is a mixture with excipients which are acceptable via the topical route, in particular cosmetically or dermatologically acceptable excipients.
또다른 특정 실시양태 변형법에 따르면, 일차 알콜 관능기를 갖는 탄수화물, 특히 다당류, 올리고당류 및(또는) 폴리올의 농도는 수성상의 0.001 중량% 내지 50 중량%, 보다 특히 0.1 중량% 내지 10 중량%이다.According to another particular embodiment variant, the concentration of carbohydrates, in particular polysaccharides, oligosaccharides and / or polyols, having a primary alcohol function is from 0.001% to 50%, more particularly from 0.1% to 10% by weight of the aqueous phase. .
유리하게는, 가교제는 다관능성 가교제, 즉 탄수화물의 일차 알콜 관능기와 특히 반응할 수 있는 반응성 관능기 2개 이상을 포함하는 가교제이며, 유리하게는 폴리카르복실산 염화물, 카르복실산 무수물, 폴리이소시아네이트, 폴리티오이소시아네이트, 폴리알데히드, 및 이들의 혼합물 중 어느 하나로부터 선택된다.Advantageously, the crosslinking agent is a polyfunctional crosslinking agent, i.e. a crosslinking agent comprising at least two reactive functional groups capable of reacting particularly with the primary alcohol functional groups of the carbohydrate, advantageously polycarboxylic acid chlorides, carboxylic acid anhydrides, polyisocyanates, Polythioisocyanate, polyaldehyde, and mixtures thereof.
탄수화물이 고분자량을 가질 경우, 이를 반응 전에 균질한 수성상에서 가수분해시킨 후 가교제와 접촉시키는 것이 바람직하다. If the carbohydrate has a high molecular weight, it is preferred to hydrolyze it in a homogeneous aqueous phase before the reaction and then contact it with a crosslinking agent.
유리하게는, 상기 방법은 가교 반응 후, 반응의 마지막에 불용성 화합물이 존재할 경우, 수성상 중에 불용성인 화합물을 제거하는 것을 포함한다.Advantageously, the method comprises removing the insoluble compound in the aqueous phase after the crosslinking reaction, if an insoluble compound is present at the end of the reaction.
특정 실시양태에서, 상기 방법은 탄수화물을 수성상 중에 용해시키고, 이어서, 이를 에탄올 및(또는) 부틸렌 글리콜과 같은 알콜에 용해될 수 있거나 그렇지 않은 가교제를 함유하는 상과, 상기 탄수화물을 가교시켜 특히 고분자량의 탄수화물의 가교된 중합체를 형성하기에 충분한 시간 동안 접촉시키는 것을 포함한다.In certain embodiments, the process dissolves carbohydrates in an aqueous phase, and then crosslinks the carbohydrates with a phase containing crosslinking agents that may or may not be dissolved in alcohols such as ethanol and / or butylene glycol, Contacting for a time sufficient to form a crosslinked polymer of high molecular weight carbohydrate.
상기 단락들에서 설명된 바와 같이, 본 발명자들은 균질한 수성상에서의 중합에 의해 고분자량의 탄수화물의 중합체를 수득하였다. 상기 방법은 반응 단계의 수와 출발 물질의 비용을 줄이고, 또한 사람에 대한 안전성을 유지하기 때문에, 공업적 제조의 관점에서 아주 유리하다.As explained in the above paragraphs, the present inventors obtained a polymer of high molecular weight carbohydrate by polymerization in a homogeneous aqueous phase. The method is very advantageous in terms of industrial production, since it reduces the number of reaction steps and the cost of starting materials and also maintains safety for humans.
수득된 중합체가 "텐싱 효과" 특성으로 알려진 특성을 가질 것임은 상상할 수 없었던 것이었다.It was unimaginable that the polymer obtained would have a property known as the "tensioning effect" property.
본 발명은 특히, 특히 일차 알콜 관능기를 통해 바람직하게는 당업자에게 공지된 다관능화제를 사용하여 가교된 다당류, 올리고당류 및(또는) 폴리올과 같은 가교된 탄수화물의 용도에 관한 것이다.The invention relates in particular to the use of crosslinked carbohydrates, such as polysaccharides, oligosaccharides and / or polyols, which are crosslinked, in particular via primary alcohol functionality, preferably using polyfunctionalizing agents known to those skilled in the art.
본 발명은 The present invention
1) 특히 다당류, 올리고당류 및(또는) 폴리올과 같은 탄화수소가 풍부한 물질을 수성상 중에 용해시키는 단계;1) dissolving a hydrocarbon-rich material, especially polysaccharides, oligosaccharides and / or polyols, in an aqueous phase;
2) 상기 기재된 바와 같이 선택된 다관능화제 (가교제)를 첨가함으로써 탄수화물을 중합하는 단계; 및2) polymerizing the carbohydrate by adding a polyfunctionalizing agent (crosslinker) selected as described above; And
3) 임의로 반응 매질 중에 불용성 (용해되지 않음)인 반응 생성물을 제거하는 단계3) optionally removing the reaction product that is insoluble (not dissolved) in the reaction medium
로 이루어진 연속적인 단계를 포함하는, 중합된 (또는 가교된) 고분자량의 일차 알콜 관능기를 포함하는 탄수화물, 예를 들어 특히 다당류, 올리고당류 및(또는) 폴리올의 제조 방법에 관한 것이다.It relates to a process for the preparation of carbohydrates, for example polysaccharides, oligosaccharides and / or polyols, comprising a polymerized (or crosslinked) high molecular weight primary alcohol function comprising a continuous step consisting of.
본 발명의 방법으로 특히 화장료 분야에서 중요한, 중합된 (가교된) 탄수화 물, 특히 다당류, 올리고당류 및(또는) 폴리올을 제조할 수 있다. 이렇게 수득된 중합된 탄수화물은 고분자량이며, 놀랍게도 완벽한 피부 내성(skin tolerance)을 제공한다.The process of the invention makes it possible to produce polymerized (crosslinked) carbohydrates, in particular polysaccharides, oligosaccharides and / or polyols, which are of particular importance in the cosmetics sector. The polymerized carbohydrates thus obtained are high molecular weight and surprisingly provide perfect skin tolerance.
본 발명의 방법의 하나의 이점은 다당류, 올리고당류 및(또는) 폴리올과 같은 탄수화물이 풍부한 물질로부터 피부의 생물기계적 특성의 개선을 유도할 수 있는 삼차원 망상체를 생성할 수 있는, 고 몰질량의 분자 구조체의 생성을 가능하게 한다는 점이다.One advantage of the method of the present invention is a high molar mass molecule capable of producing three-dimensional reticular from which carbohydrate-rich materials such as polysaccharides, oligosaccharides and / or polyols can lead to an improvement in the biomechanical properties of the skin. It allows you to create structures.
가교화도는 확인가능하지 않기 때문에, 본 발명에 따른 가교된 중합체에 대한 명확한 방식의 정의를 제공하는 것이 쉽지 않다. 예를 들어, 본 발명자들은 "고분자량 중합체"라는 용어를, 상당 부분의 쇄의 분자량이 50,000 달톤 이상인 중합체, 특히 분자량이 바람직하게는 150,000 달톤 이상, 보다 바람직하게는 300,000 달톤 이상인 가교된 다당류라는 의미로 사용한다.Since the degree of crosslinking is not identifiable, it is not easy to provide a definite way of defining the crosslinked polymer according to the invention. For example, we refer to the term "high molecular weight polymer" as a polymer having a substantial portion of the chain having a molecular weight of at least 50,000 Daltons, in particular crosslinked polysaccharides having a molecular weight of preferably at least 150,000 Daltons, more preferably at least 300,000 Daltons. Used as.
본 발명의 방법의 다른 추가의 또는 별도의 특징은 하기와 같다:Other additional or separate features of the process of the invention are as follows:
- 탄수화물, 특히 다당류, 올리고당류 및(또는) 폴리올이 풍부한 물질은 바람직하게는 식물 기원, 동물 기원 및(또는) 생명공학적 기원 (예를 들어 발효)로 이루어진 천연 물질로부터 선택된다.Materials rich in carbohydrates, in particular polysaccharides, oligosaccharides and / or polyols, are preferably selected from natural substances of vegetable origin, animal origin and / or biotechnological origin (eg fermentation).
- 상기 물질을 20 g/L 내지 500 g/L의 속도로 수성상 중에 용해시킨다.The material is dissolved in the aqueous phase at a rate of 20 g / L to 500 g / L.
특정 실시양태에 따르면, 상기 언급한 일차 관능기를 갖는 다당류, 올리고당류 및(또는) 폴리올은 하기로 이루어진 군으로부터 선택된다:According to certain embodiments, the polysaccharides, oligosaccharides and / or polyols having the aforementioned primary functional groups are selected from the group consisting of:
● 하기 다당류:● the following polysaccharides:
- 갈락토만난, 예를 들어 비스코검(Viscogum; 등록상표)(사노피(SANOFI))과 같은 구아(guar) 기원, 또는 리곰메(Lygomme; 등록상표)(사노피) 또는 메이프로-플루어(Meypro-Fleur; 등록상표) 또는 메이프로딘(Meyprodyn; 등록상표)(메이홀(MEYHALL))이라는 상품명으로 시판되는 캐럽(carob) 기원의 갈락토만난;Galactomannans, for example guar origins such as Viscogum® (SANOFI), or Lygomme® (Sanopy) or Maypro-Fluor (Meypro) Galactomannans of carob origin sold under the trade name Fleur® or Meyprodyn® (MEYHALL);
- 사티아겔(Satiagel; 등록상표) 또는 사티아검(Satiagum; 등록상표)(데구사(DEGUSSA)) 또는 제누비스코(Genuvisco; 등록상표)(허큘레스(HERCULES))라는 상품명으로 시판되는 홍조류로부터 추출된 카라게난;From red algae sold under the name Satiagel® or Satiagum® (DEGUSSA) or Genuvisco® (HERCULES). Extracted carrageenan;
- 누트리콜(Nutricol; 등록상표)(FMC 코포레이션(FMC Corporation)) 또는 프로폴(Propol; 등록상표)(FMC 쉬이츠(FMC SCHIITZU))이라는 상품명으로 시판되는 곤약 검 기원의 글루코만난;Glucomannan from the konjac gum marketed under the trade names Nutricol® (FMC Corporation) or Propol® (FMC SCHIITZU);
- 크산탄(Xanthane)(켈코(KELKO)), 겔란(Gellane; 등록상표)(켈코), 쿠드란(Curdlane; 등록상표)(다께다(TAKEDA)) 또는 히알루론산과 같은, 발효 기원의 일차 알콜 관능기를 갖는 다당류;Primary alcohols of fermentation origin, such as Xanthane (KELKO), Gellan® (Kelko), Curdlane® (TAKEDA) or hyaluronic acid Polysaccharides having functional groups;
- 나트로솔(Natrosol; 등록상표) 250HHX (아쿠알론(AQUALON)), 클루셀 EF(Klucel EF; 등록상표)(아쿠알론), 비바푸르(Vivapur; 등록상표)(인스텔 키모스(Instel Chimos))와 같은 셀룰로스;Natrosol (R) 250HHX (AQUALON), Klucel EF (R) (Aqualon), Vivapur (R) (Instel Chimos) Cellulose such as;
- 히드록시프로필 메틸 셀룰로스 (아쿠알론), 메틸 에틸 셀룰로스 (아쿠알론), 메틸 히드록시 메틸 셀룰로스 (아쿠알론) 또는 블라노스(Blanose; 등록상표)(아쿠알론)와 같은 셀룰로스 유도체;Cellulose derivatives such as hydroxypropyl methyl cellulose (aqualon), methyl ethyl cellulose (aqualon), methyl hydroxy methyl cellulose (aqualon) or Blanose® (aqualon);
- 덱스트란(Dextran; 등록상표), 덱스트란 T70, T500 또는 T2000, 덱스트란 술페이트 (파마시아 파인 케미칼즈(Pharmacia Fine Chemicals))와 같은 폴리홀로시드;Polyholoxides such as Dextran®, Dextran T70, T500 or T2000, Dextran sulfate (Pharmacia Fine Chemicals);
- 식품 등급의 한천 (시그마(Sigma)), 세균성 한천 (세텍삼(Setexam)), 모노가르(Monogar) M540 한천 (세텍삼) 또는 한천 QSN5 (세텍삼)와 같은 한천;Agar, such as food grade agar (Sigma), bacterial agar (Setexam), Monogar M540 agar (Seteksam) or agar QSN5 (Seteksam);
- 알긴산의 나트륨염 A2158 (시그마), 사티알긴(Satialgine; 등록상표)(데구사) 또는 알긴산나트륨 FD 125 (다니스코(Danisco))와 같은 알기네이트;Alginates such as sodium salt of alginic acid A2158 (Sigma), Satialgin® (Degussa) or sodium alginate FD 125 (Danisco);
- 아밀로펙틴 (플루카(Fluka)), 아밀로스 (플루카), 나스타(Nastar; 등록상표)(코수크라(Cosucra)), 왁시 메이즈 스타치(Waxy Maize starch)(로케뜨(Roquette)), 왁실리스(Waxillis; 등록상표)(로케뜨), 밀 유래의 전분 (로케뜨), 쌀 유래의 전분 (로케뜨), 감자 유래의 전분 (로케뜨) 또는 옥수수 유래의 전분 (로케뜨)과 같은 전분;Amylopectin (Fluka), Amylose (Fluka), Nastar® (Cosucra), Wax Maize starch (Roquette), Waxil Starches such as Waxillis® (rocket), starch derived from wheat (rocket), starch derived from rice (rocket), starch derived from potato (rocket) or starch derived from corn (rocket) ;
- 키타머(Kitamer; 등록상표)(유니펙스(Unipex))와 같은 키토산;Chitosans, such as Kitamer (Unipex);
- 퓨어글루칸(Pureglucan; 등록상표)(다께다)과 같은 쿠드란;Cudrans such as Pureglucan® (cold);
- 아드라간트 검 또는 트라가칸트 검 (에미가(Emiga));Adragant gum or tragacanth gum (Emiga);
- 아라비아 검 또는 아카시아 검 (콜린(Colin)) 또는 발검(Valgum; 등록상표)(발마(Valmar));Arabian gum or acacia gum (Colin) or Valgum (registered trademark) (Valmar);
- 치아 검(Chia gum)(시그마);Chia gum (Sigma);
- 엘레미 검(Gum elemi)(에미가);Gum elemi (Emiga);
- 켈코겔(Kelcogel; 등록상표)(SPCI)과 같은 겔란 검(Gellan gum);Gelan gum such as Kelcogel® (SPCI);
- 가티 검(Gum ghatti) 또는 인디안 검(Indian gum)(시그마);Gum ghatti or Indian gum (Sigma);
- 카라야 검(gum karaya)(시그마);Gum karaya (sigma);
- 셸락(Shellac)(시그마);Shellac (Sigma);
- 마닐라 검(Manilla gum)(시그마);Manilla gum (Sigma);
● 하기를 예로 하는 이하의 올리고당류, 단당류 또는 이당류 (별도로 표시하지 않는 한, 시그마사로부터 시판됨): The following oligosaccharides, monosaccharides or disaccharides (commercially available from Sigma unless otherwise indicated):
- 시클로덱스트린 (특히, α, β 또는 γ 시클로덱스트린 또는 이들의 유도체),Cyclodextrins (especially α, β or γ cyclodextrins or derivatives thereof),
- 덱스트린 (글루시덱스 40(Glucidex 40; 등록상표) 또는 글루시덱스 47(Glucidex 47; 등록상표), 로케뜨);Dextrin (Glucidex 40® or Glucidex 47®, rocket);
- 라피노스, 셀로비오스, 수크로스, 말토스, 락토스, 트레할로스, 디히드록시아세톤 (DHA), 프룩토스, 소르보스, 리보스, 데옥시리보스, 크실로스, 아라비노스, 글루코스, 만노스, 갈락토스, 에리트로스, 트레오스, 알로스, 아트로스, 굴로스, 이도스, 탈로스, 에리트룰로스, 크실룰로스, 프사이코스, 타가토스, 세도헵툴로스, 크실로비오스, 키토비오스, 니게로스, 아미나리비오스, 코지비오스, 소포로스, 겐티아노스, 겐티오비오스, 멜리비오스, 멜레지토스, 투라노스, 스타키오스, 베르바스코스;-Raffinose, cellobiose, sucrose, maltose, lactose, trehalose, dihydroxyacetone (DHA), fructose, sorbose, ribose, deoxyribose, xylose, arabinose, glucose, mannose, galactose, erythrose , Treos, allose, atheros, gulose, idos, talos, erythrulose, xylose, psychos, tagatose, sedoheptulose, xylobiose, chitobiose, nigerose, aminaribis , Cozibiose, sophorose, gentianose, genthiobiose, melibiose, melezitose, turanos, stachiose, verbascose;
- 글루콘산, 글루코노락톤, 글루코사민, 갈락토사민, 갈락토사민 술페이트, 글루코사민 술페이트;Gluconic acid, gluconolactone, glucosamine, galactosamine, galactosamine sulfate, glucosamine sulfate;
- 퀼라야(quillaya)의 수피 유래의 사포닌과 같은 사포닌;Saponins, such as saponins from the bark of quillaya;
- 구아노신, 우리딘;Guanosine, uridine;
- 스트렙토마이신 술페이트;Streptomycin sulfate;
- 리보플라빈; 및Riboflavin; And
● 하기를 예로 하는 이하의 폴리올 (별도로 표시하지 않는 한, 로케뜨사로부터 시판됨):The following polyols (commercially available from Rocket Corporation unless otherwise indicated):
- 글리세롤, 소르비톨, 에리트리톨 (시그마), 말티톨, 소르비톨, 만니톨, 락티톨 (시그마), 갈락티톨 (시그마), 리비톨 (시그마), 글리세롤 (시그마), 크실리톨, 미로-이노시톨, 폴리에틸렌 글리콜 또는 분자량에 따라 다양한 중합 수준을 갖는 PEG 등.-Glycerol, sorbitol, erythritol (sigma), maltitol, sorbitol, mannitol, lactitol (sigma), galactitol (sigma), ribitol (sigma), glycerol (sigma), xylitol, miro-inositol, polyethylene glycol Or PEG with varying levels of polymerization, depending on molecular weight.
특정 실시양태에 따르면, 상기 언급된 일차 관능기를 갖는 다당류, 올리고당류 및(또는) 폴리올은, 바람직하게는 세바스산 디클로라이드 또는 테레프탈산 디클로라이드와 가교된, 크산탄의 다당류, 셀룰로스, 캐럽 유래의 검, 크실리톨, 말토스, 카라게난, 라피노스, 아카시아 검, 글리세롤 (예를 들어 10%, w/w)과 크산탄 (예를 들어 2%, w/w)의 혼합물, 만니톨 (예를 들어 10%, w/w)과 이눌린 (예를 들어 5%, w/w)의 혼합물 및 이들의 혼합물 중 어느 하나로 이루어진 군으로부터 바람직하게 선택된다.According to a particular embodiment, the polysaccharides, oligosaccharides and / or polyols having the above-mentioned primary functional groups are gums derived from polysaccharides, celluloses and carbs of xanthan, preferably crosslinked with sebacic acid dichloride or terephthalic acid dichloride. , Xylitol, maltose, carrageenan, raffinose, acacia gum, a mixture of glycerol (eg 10%, w / w) and xanthan (eg 2%, w / w), mannitol (eg 10%, w / w) and inulin (for example 5%, w / w), and mixtures thereof.
특정 실시양태에 따르면, 상기 언급된 일차 관능기를 갖는 다당류, 올리고당류 및(또는) 폴리올은 세바스산 디클로라이드와 가교된 크산탄의 다당류, 세바스산 디클로라이드와 가교된 셀룰로스, 세바스산 디클로라이드와 가교된 캐럽 유래의 검, 세바스산 디클로라이드와 가교된 크실리톨, 세바스산 디클로라이드와 가교된 말토스, 테레프탈산 디클로라이드와 가교된 카라게난, 테레프탈산 디클로라이드와 가 교된 라피노스, 테레프탈산 디클로라이드와 가교된 아카시아 검, 테레프탈산 디클로라이드와 가교된 글리세롤 (예를 들어 10%, w/w)과 크산탄 (예를 들어 2%, w/w)의 혼합물, 테레프탈산 디클로라이드와 가교된 만니톨 (예를 들어 10%, w/w)과 이눌린 (예를 들어 5%, w/w)의 혼합물 및 이들의 혼합물 중 어느 하나로 이루어진 군으로부터 바람직하게 선택된다.According to certain embodiments, the polysaccharides, oligosaccharides and / or polyols having the aforementioned primary functional groups are cross-linked with polysaccharides of xanthan crosslinked with sebacic acid dichloride, cellulose crosslinked with sebacic acid dichloride, and sebacic acid dichloride. Gum derived from carbohydrate, xylitol crosslinked with sebacic acid dichloride, maltose crosslinked with sebacic acid dichloride, carrageenic crosslinked with terephthalic acid dichloride, raffinose crosslinked with terephthalic acid dichloride, crosslinked with terephthalic acid dichloride Acacia gum, a mixture of glycerol (eg 10%, w / w) crosslinked with terephthalic acid dichloride and xanthan (eg 2%, w / w), mannitol crosslinked with terephthalic acid dichloride (eg 10 %, W / w) and inulin (for example 5%, w / w), and mixtures thereof, preferably It is chosen.
유리한 실시양태에 따르면, 제조 방법은, 일차 알콜 관능기를 갖는 탄수화물, 특히 다당류 및(또는) 올리고당류 및(또는) 폴리올을 수성상 중에 용해시킨 후, 탄수화물의 일차 알콜 관능기와 가교제의 반응성 관능기 간의 중합을 수행하기 위해, 상기 탄화수소를 함유하는 수성상과, 바람직하게는 탄수화물의 일차 알콜 관능기와 반응할 수 있는 관능기를 갖는 에탄올 및(또는) 부틸렌 글리콜과 같은 알콜 중에 용해될 수 있거나, 그렇지 않은 가교제를 함유하는 상을, 고분자량의 중합된 탄수화물을 얻기에 충분한 시간 동안 접촉시키는 것을 특징으로 한다.According to an advantageous embodiment, the process for the preparation comprises dissolving carbohydrates, in particular polysaccharides and / or oligosaccharides and / or polyols, having a primary alcohol function in the aqueous phase, followed by polymerization between the primary alcohol function of the carbohydrate and the reactive functional groups of the crosslinker. To carry out the crosslinking agent, which may or may not be dissolved in an aqueous phase containing the hydrocarbon and in alcohols such as ethanol and / or butylene glycol, preferably having a functional group capable of reacting with the primary alcohol function of the carbohydrate. The phase containing is characterized by contacting for a time sufficient to obtain a high molecular weight polymerized carbohydrate.
본 발명에 따른 방법의 변형법인 실시양태에 따르면, 가교제는 다가산 염화물, 다가산 무수물, 폴리이소시아네이트, 폴리티오이소시아네이트, 폴리알데히드 및 이들의 혼합물 중 어느 하나로 이루어진 군으로부터 선택된다. 가교제로는 반응의 중화 이후에 분리 조작을 수행하지 않아도 되는, 피부에 허용되는 비반응성 부분이 유리하게 선택될 수 있다.According to an embodiment, which is a variant of the process according to the invention, the crosslinking agent is selected from the group consisting of any of polyhydric chlorides, polyacid anhydrides, polyisocyanates, polythioisocyanates, polyaldehydes and mixtures thereof. As the crosslinking agent, nonreactive moieties that are acceptable to the skin can be advantageously selected, which do not require a separation operation after neutralization of the reaction.
다가산 염화물은 예를 들어 산 삼염화물 또는 산 이염화물부터 선택되어 에스테르 결합을 형성한다.The polyacid chloride is for example chosen from acid trichloride or acid dichloride to form ester linkages.
유리하게는, 알콜에 용해된 가교제의 중량 비율은 일반적으로 5 내지 30%이 나, 바람직하게는 10 내지 20%이다.Advantageously, the weight ratio of crosslinking agent dissolved in alcohol is generally from 5 to 30%, preferably from 10 to 20%.
바람직한 특징에 따르면, 가교제는 프탈산 트리클로라이드, 프탈산 디클로라이드, 세바스산 디클로라이드, 아젤라산 디클로라이드, 숙신산 디클로라이드, 예를 들어 시트르산과 같은 트리카르복실산의 디클로라이드 또는 트리클로라이드로부터 선택된다. 다가산 무수물은 예를 들어 숙신산 이무수물 또는 말레산 이무수물과 같은 산 이무수물이다.According to a preferred feature, the crosslinking agent is selected from phthalic acid trichloride, phthalic acid dichloride, sebacic acid dichloride, azelaic acid dichloride, succinic acid dichloride, for example dichlorides or trichlorides of tricarboxylic acids such as citric acid. Polyacid anhydrides are acid dianhydrides such as, for example, succinic dianhydride or maleic dianhydride.
본 발명에 따른 방법의 다른 특히 유리한 실시양태에 따르면, 수성상은 알칼리 수성상, 즉 pH가 7 초과의 알칼리성이다. 바람직한 pH 범위는 약 7.1 내지 약 10이다. 보다 바람직한 pH 범위는 8 내지 10, 바람직하게는 8 내지 9이다. KOH 또는 NaOH와 같은 강염기, 또는 암모니아 용액, 보레이트, 포스페이트 또는 카르보네이트와 같은 약염기는 수성상을 염기성 pH로 바꾸기 위한 염기로서 사용될 수 있다. According to another particularly advantageous embodiment of the process according to the invention, the aqueous phase is an alkaline aqueous phase, ie an alkali with a pH greater than 7. Preferred pH ranges are from about 7.1 to about 10. More preferred pH range is 8-10, preferably 8-9. Strong bases such as KOH or NaOH, or weak bases such as ammonia solution, borate, phosphate or carbonate can be used as the base for converting the aqueous phase to basic pH.
본 발명에 따른 탄수화물의 가교된 중합체는 국소 조성물, 특히 화장료 조성물, 피부-제약 조성물 또는 제약 조성물의 형태로 제조된다. 이로부터 상기 조성물용의 부형제는, 예를 들어 보존제, 연화제, 유화제, 계면활성제, 수분제, 증점제, 경화제, 매티화잉제(matifying agent), 안정화제, 산화방지제, 직제(texture agent), 증백제, 필모제닉제(filmogenic agent), 가용화제, 안료, 염료, 향료 및 태양 필터로 이루어진 군으로부터 선택된 1종 이상의 화합물을 함유한다. 이러한 부형제는 아미노산 및 이의 유도체, 폴리글리세롤, 에스테르, 셀룰로스의 중합체 및 유도체, 라놀린 유도체, 포스포리피드, 락토페린, 락토퍼옥시데이즈, 수크로스 계 안정화제, 비타민 E 및 이의 유도체, 천연 및 합성 왁스, 식물성유, 트리글리세리드, 비감화물(insaponifiable), 피토스테롤, 식물 에스테르, 실리콘 및 이의 유도체, 단백질 가수분해물, 호호바유 및 이의 유도체, 지용성/수용성 에스테르, 베타인, 아민옥시드, 식물 추출물, 수크로스의 에스테르, 이산화티타늄, 글리신 및 파라벤으로 이루어진 군, 보다 바람직하게는 부틸렌 글리콜, 스테아레트-2, 스테아레트-21, 글리콜-15 스테아릴 에테르, 카테아릴 알콜, 페녹시에탄올, 메틸파라벤, 에틸파라벤, 프로필파라벤, 부틸파라벤, 부틸렌 글리콜, 천연 토코페롤, 글리세롤, 나트륨 디히드록시세틸, 이소프로필 히드록시세틸 에테르, 글리콜 스테아레이트, 트리이소노나오인, 옥틸 코코에이트, 폴리아크릴아미드, 이소파라핀, 라우레트-7, 카르보머(carbomer), 프로필렌 글리콜, 글리세롤, 비스아볼올, 디메티콘, 수산화나트륨, PEG 30-디폴리히드록시스테레이트, 카프르/카프릴산 트리글리세리드, 카테아릴 옥타노에이트, 디부틸 아디페이트, 포도씨유, 호호바유, 황화마그네슘, EDTA, 시클로메티콘, 크산탄 검, 시트르산, 나트륨 라우릴 술페이트, 광랍 및 광유, 이소스테아릴 이소스테아레이트, 프로필렌 글리콜 디페라르고네이트, 프로필렌 글리콜 이소스테아레이트, PEG 8 밀랍, 목심부의 수소화 팜유 글리세리드, 수소화 팜유 글리세리드, 라놀린유, 참깨유, 세틸 락테이트, 라놀린 알콜, 피마자유, 이산화티타늄, 락토스, 수크로스, 저밀도 폴리에틸렌 및 등장성 염수 용액으로 이루어진 군으로부터 바람직하게 선택된다.The crosslinked polymers of carbohydrates according to the invention are prepared in the form of topical compositions, in particular cosmetic compositions, skin-pharmaceutical compositions or pharmaceutical compositions. The excipients for the composition therefrom are, for example, preservatives, emollients, emulsifiers, surfactants, moisture agents, thickeners, hardeners, matifying agents, stabilizers, antioxidants, texture agents, brighteners. And at least one compound selected from the group consisting of filmogenic agents, solubilizers, pigments, dyes, perfumes and solar filters. Such excipients include amino acids and derivatives thereof, polyglycerols, esters, polymers and derivatives of cellulose, lanolin derivatives, phospholipids, lactoferrins, lactoperoxidases, sucrose-based stabilizers, vitamin E and derivatives thereof, natural and synthetic waxes, Vegetable oils, triglycerides, insaponifiable, phytosterols, plant esters, silicones and derivatives thereof, protein hydrolysates, jojoba oil and derivatives thereof, fat soluble / water soluble esters, betaine, amine oxides, plant extracts, esters of sucrose , Titanium dioxide, glycine and parabens, more preferably butylene glycol, stearet-2, stearet-21, glycol-15 stearyl ether, catearyl alcohol, phenoxyethanol, methylparaben, ethylparaben, Propylparaben, Butylparaben, Butylene Glycol, Natural Tocopherol, Glycerol, Sodium Dihydroxy Methyl, isopropyl hydroxycetyl ether, glycol stearate, triisononaoin, octyl cocoate, polyacrylamide, isoparaffin, lauret-7, carbomer, propylene glycol, glycerol, bisavool, Dimethicone, sodium hydroxide, PEG 30-dipolyhydroxysterate, capric / caprylic triglyceride, catearyl octanoate, dibutyl adipate, grapeseed oil, jojoba oil, magnesium sulfide, EDTA, cyclomethicone, Xanthan gum, citric acid, sodium lauryl sulfate, broad and mineral oil, isostearyl isostearate, propylene glycol diferargonate, propylene glycol isostearate, PEG 8 beeswax, hydrogenated palm oil glycerides in the core, hydrogenated palm oil glycerides, Lanolin oil, sesame oil, cetyl lactate, lanolin alcohol, castor oil, titanium dioxide, lactose, sucrose, low density polyethylene It is preferably selected from the group consisting of isotonic salt solution.
유리하게는, 상기 언급된 조성물은 수성이거나 오일성인 용액, 특히 포트 또는 튜브 중의 크림 또는 수용성 겔 또는 지용성 겔, 특히 샤워 겔, 샴푸; 밀크; 특 히 수-중-유형 또는 유-중-수형 또는 복합물 또는 실리콘-함유물인 에멀젼, 마이크로에멀젼 또는 나노에멀젼; 특히 유리병, 플라스틱병, 계측병, 에어로졸 중의 로션; 앰풀; 액상 비누; 피부형 바아; 연고; 발포제; 및 바람직하게는 액상, 페이스트상 또는 고체상, 예를 들어 스틱, 특히 립스틱의 형태의 무수물 생성물로 이루어진 군으로부터 선택된 형태로 제제화된다.Advantageously, the abovementioned compositions can be used in aqueous or oily solutions, in particular creams or water soluble gels or fat soluble gels, in particular shower gels, shampoos in pots or tubes; milk; Emulsions, microemulsions or nanoemulsions, in particular water-in-type or oil-in-water or complexes or silicone-containing; Lotions in glass bottles, plastic bottles, measuring bottles, aerosols, in particular; ampoule; Liquid soaps; Skin type bars; Ointment; blowing agent; And preferably in the form selected from the group consisting of anhydride products in the form of liquids, pastes or solids, for example sticks, especially lipsticks.
본 발명의 다른 목적, 특징 및 장점은, 단지 예시로서 주어지고 본 발명의 범위를 제한하지 않는 실시예를 참조하는 상세한 설명을 읽음으로써 당업자에게 명백하게 드러날 것이다. Other objects, features and advantages of the present invention will become apparent to those skilled in the art upon reading the detailed description, which refers to embodiments, which are given by way of illustration only and not limiting the scope of the invention.
실시예는 본 발명의 일부를 이루며, 실시예를 포함하여, 전체로서 포함되는 발명의 상세한 설명으로부터의 임의의 선행기술에 대해 신규한 것으로 여겨지는 임의의 특징은 이의 기능성 및 이의 일반성에서 본 발명의 일부를 이룬다.The examples form part of the present invention, and any features believed to be novel with respect to any prior art from the description of the invention, including the examples as a whole, include, by way of example, their functionality and generality thereof. Forms part of it.
따라서, 모든 실시예는 일반적인 범위를 갖는다.Accordingly, all embodiments have a general scope.
또한, 실시예에서, 별도로 나타내지 않는 한, 모든 백분율은 중량 기준이고, 별도로 나타내지 않는 한 온도는 섭씨 온도로 표현되며, 별도로 나타내지 않는 한 압력은 대기압이다.In addition, in the examples, unless otherwise indicated, all percentages are by weight and unless otherwise indicated, the temperature is expressed in degrees Celsius, and unless otherwise indicated, the pressure is atmospheric pressure.
<실시예><Example>
실시예 1 : 2% 크산탄 수용액의 가교 및 인간 피부에 대한 텐싱 효과의 증명Example 1 Crosslinking of 2% Xanthan Aqueous Solution and Demonstration of Tensioning Effect on Human Skin
1- 다음과 같이 크산탄의 다당류 (5,000,000 Da)를 제조하였다: 크산탄 (켈트롤(KELTROL), SPCI사) 2.10 g을 냉각, 탈염수 93.1 g에 용해시켰다. 이어서 강 한 교반 하에 NaHCO3 4.8 g을 제조생성물에 첨가하였다. 용해를 완료한 후에, pH는 8 내지 8.4의 값으로 안정화시켰다. 1- Polysaccharides of xanthan (5,000,000 Da) were prepared as follows: 2.10 g of xanthan (KELTROL, SPCI) was cooled and dissolved in 93.1 g of demineralized water. Then 4.8 g of NaHCO 3 was added to the preparation under strong stirring. After complete dissolution, the pH was stabilized to a value of 8 to 8.4.
2- 가교제의 제조: 세바스산 디클로라이드 0.75 g을 부틸렌 글리콜 4.25 g 에 용해시켰다. Preparation of 2-crosslinker: 0.75 g of sebacic acid dichloride was dissolved in 4.25 g of butylene glycol.
3- 크산탄 수용액의 가교: 교반 하에 2에서 제조한 용액을 1에서 제조한 용액에 첨가하였다. 교반 하에 전체 용액을 60분 동안 두어, 한편의 활성화된 이산과 다른 한편의 다당류의 알콜 작용기 간의 중합을 초래하였다. 이 반응은 염기성 매질에서 촉진된다. 반응 후에, 가교된 크산탄 용액은 불용성 물질을 포함하지만 그대로 사용할 수 있다. 예를 들어, 0.22 ㎛의 컷-오프(cut-off) 입구(threshold)를 포함하는 장치 상에서 행하는 여과에 의해 생성물을 여과하여 불용성 물질을 제거할 수 있다. Crosslinking of 3-Xanthan Aqueous Solution: The solution prepared in 2 was added to the solution prepared in 1 under stirring. The entire solution was left under stirring for 60 minutes, resulting in polymerization between the activated diacid on the one hand and the alcohol functional groups of the polysaccharide on the other. This reaction is promoted in basic medium. After the reaction, the crosslinked xanthan solution contains an insoluble substance but can be used as it is. For example, the product can be filtered to remove insoluble matter by filtration on an apparatus comprising a cut-off threshold of 0.22 μm.
4- 텐싱 효과의 측정 원리: 본 발명에 의해 제조된 중합된 다당류의 미용 효과에 대한 피부의 생물기계적 특성을 기술하기 위해서, 특히 시판명 "비디오 디지털 변환기(Video Digitizer(등록상표)" (커리지 등(Courage et), 카자카사(Khazaka))으로 시판되는 장치를 사용하여 텐싱 효과를 측정하였다. 이러한 장치로서, 피부의 거칠기 파라미터를 측정할 수 있고, 이는 "첨곡(peaks and valleys)"의 형태로 존재하는 피부의 릴리프(relief) 이미지에 의해 측정된다. 거칠기가 줄어들수록, 텐싱 효과는 커진다. 4-Principle of Tensioning Effect: In order to describe the biomechanical properties of the skin on the cosmetic effect of the polymerized polysaccharides produced according to the invention, in particular the commercially available "Video Digitizer®" (collage et al. The tensioning effect was measured using a device commercially available from Courage et, Kazaka, which measures the roughness parameter of the skin, which is in the form of "peaks and valleys." Measured by a relief image of the existing skin, the less roughness, the greater the tensioning effect.
상박 위에 두 측정 부위 (2cm x 2cm)를 결정하고, 제1 부위에 3에서 제조한 용액 50 mg을 도포하였다. 제2 부위에 비-가교된 중합체 용액 50 mg을 도포하였다. 1분 동안 건조시킨 후에, ≪비디오 디지털 변환기(등록상표)≫를 사용하여 부피 파라미터를 측정하였다. 측정치의 양호한 동차성을 위해 10회 반복하여 측정하였다. 처리한 후에 측정시, 텐싱 효과는 거칠기의 감소를 초래하였다. Two measurement sites (2 cm x 2 cm) were determined on the upper arm and 50 mg of the solution prepared in 3 was applied to the first site. 50 mg of the non-crosslinked polymer solution was applied to the second site. After drying for 1 minute, the volume parameters were measured using a `` Video Digital Converter® ''. The measurement was repeated 10 times for good homogeneity of the measurements. When measured after treatment, the tensioning effect resulted in a reduction in roughness.
다음 표에 결과를 나타내었다: The results are shown in the following table:
이 시험에 의해 본 발명의 생성물이 건강한 지원자의 피부에서 유의한 텐싱 효과를 초래할 수 있다는 것이 증명되었다. This test demonstrated that the product of the present invention can lead to a significant tensioning effect in the skin of healthy volunteers.
실시예 2 : 2% 크산탄 수용액의 가교Example 2 Crosslinking of 2% Xanthan Aqueous Solution
실시예 1의 단계 1 동안에, 1%의 트리나트륨 시트레이트를 2% 크산탄 용액에 첨가하였다. 다른 단계 모두는 동일하였다. 텐싱 효과는 실시예 1에서 얻은 효과와 유사하였다. During Step 1 of Example 1, 1% trisodium citrate was added to the 2% xanthan solution. All other steps were identical. The tensioning effect was similar to the effect obtained in Example 1.
실시예 3 : 2% 크산탄 수용액의 가교Example 3 Crosslinking of 2% Xanthan Aqueous Solution
실시예 1의 단계 1 동안에, 0.4%의 (트리스[히드록시메틸]아미노메탄)을 2% 크산탄 용액에 첨가하였다. 다른 단계 모두는 동일하였다. 텐싱 효과는 실시예 1에서 얻은 효과와 유사하였다. During Step 1 of Example 1, 0.4% of (tris [hydroxymethyl] aminomethane) was added to a 2% xanthan solution. All other steps were identical. The tensioning effect was similar to the effect obtained in Example 1.
실시예 4 : 2% 크산탄 수용액의 가교Example 4 Crosslinking of 2% Xanthan Aqueous Solution
실시예 1의 단계 1 동안에, 0.5%의 인산이나트륨을 2% 크산탄 용액에 첨가 하였다. 다른 단계 모두는 동일하였다. 텐싱 효과는 실시예 1에서 얻은 효과와 유사하였다. During Step 1 of Example 1, 0.5% disodium phosphate was added to the 2% xanthan solution. All other steps were identical. The tensioning effect was similar to the effect obtained in Example 1.
실시예 5 : 셀룰로스 수용액의 가교 및 감각 평가Example 5 Crosslinking and Sensory Evaluation of Aqueous Cellulose Solution
1- 다음과 같이 셀룰로스 (1,000,000 Da) 수용액을 제조하였다: 나트로솔(Natrosol)(등록상표) 250HHX 0.56 g을 냉각, 탈염수 94.64 g에 용해시켰다. 이어서 강한 교반 하에 NaHCO3 4.8 g을 제조생성물에 첨가하였다. 용해를 완료한 후에, pH는 8 내지 8.4의 값으로 안정화시켰다. 1- Aqueous solution of cellulose (1,000,000 Da) was prepared as follows: 0.56 g of Natrosol® 250HHX was dissolved in 94.64 g of cooled, demineralized water. Then 4.8 g of NaHCO 3 was added to the preparation under strong stirring. After complete dissolution, the pH was stabilized to a value of 8 to 8.4.
2- 가교제의 제조: 세바스산 디클로라이드 1.5 g을 부틸렌 글리콜 8.5 g에 용해시켰다. Preparation of the 2-crosslinker: 1.5 g of sebacic acid dichloride was dissolved in 8.5 g of butylene glycol.
3- 셀룰로스 수용액의 가교: 교반 하에 2에서 제조한 용액을 1에서 제조한 용액에 첨가하였다. 교반 하에 전체 용액을 60분 동안 두어, 한편의 활성화된 이산과 다른 한편의 다당류의 알콜 작용기 간의 중합을 초래하였다. 이 반응은 염기성 매질에서 촉진된다. 반응 후에, 가교된 나트로솔(등록상표) 250HHX 용액을 그대로 사용하였다. Crosslinking of 3-cellulose aqueous solution: The solution prepared in 2 was added to the solution prepared in 1 under stirring. The entire solution was left under stirring for 60 minutes, resulting in polymerization between the activated diacid on the one hand and the alcohol functional groups of the polysaccharide on the other. This reaction is promoted in basic medium. After the reaction, crosslinked Natrosol® 250HHX solution was used as is.
4- 텐싱 효과의 측정 원리: 상박 위에 두 측정 부위 (2cm x 2cm)를 결정하고, 제1 부위에 가교된 나트로솔(등록상표) 250HHX 용액 50 mg을 도포하였다. 제2 부위에 비가교된 나트로솔(등록상표) 250HHX 용액 50 mg을 도포하였다.4- Measuring principle of tensioning effect: Two measurement sites (2 cm × 2 cm) were determined on the upper arm and 50 mg of a cross-linked Natrosol® 250HHX solution was applied to the first site. 50 mg of uncrosslinked Natrosol® 250HHX solution was applied to the second site.
1분 동안 건조시킨 후에, 지원자 패널들이 감각 평가하여 토닝 감각을 기록하였다.After drying for 1 minute, volunteer panels sensed and recorded the toning sensation.
이 시험에 의해 본 발명의 생성물이 건강한 지원자의 피부에서 감각 평가에 의해 감지될 수 있는 유의한 텐싱 효과를 초래한다는 것이 증명되었다. This test demonstrated that the product of the invention results in a significant tensioning effect that can be detected by sensory evaluation in the skin of healthy volunteers.
실시예 6 : 캐럽 검 (300,000 Da) 수용액의 가교Example 6 Crosslinking of Carob Gum (300,000 Da) Aqueous Solution
실시예 5의 단계 1 동안에, 5% 캐럽 용액, 및 바람직하게는 2% 캐럽 용액을 제조하였다. 다른 단계 모두는 동일하였다. 텐싱 효과는 실시예 5에서 얻은 효과와 유사하였다. During step 1 of Example 5, a 5% carob solution, and preferably a 2% carob solution, was prepared. All other steps were identical. The tensioning effect was similar to the effect obtained in Example 5.
실시예 7 : 크실리톨 (152 Da) 수용액의 가교Example 7 Crosslinking of Xylitol (152 Da) Aqueous Solution
실시예 5의 단계 1 동안에, 5% 크실리톨 용액을 제조하였다. 다른 단계 모두는 동일하였다. 텐싱 효과는 실시예 5에서 얻은 효과와 유사하였다.During Step 1 of Example 5, a 5% xylitol solution was prepared. All other steps were identical. The tensioning effect was similar to the effect obtained in Example 5.
실시예 8 : 말토스 (342 Da) 수용액의 가교Example 8 Crosslinking of Maltose (342 Da) Aqueous Solution
실시예 5의 단계 1 동안에, 20% 말토스 용액을 제조하였다. 다른 단계 모두는 동일하였다. 텐싱 효과는 실시예 5에서 얻은 효과와 유사하였다. During step 1 of Example 5, a 20% maltose solution was prepared. All other steps were identical. The tensioning effect was similar to the effect obtained in Example 5.
실시예 9a : 카라게난 수용액의 가교: 레올로지의 변형Example 9a Crosslinking of an Carrageenan Aqueous Solution: Modification of Rheology
1- 다음과 같이 카라게난 (제누비스코(등록상표), 허큘레스사) (500,000 Da) 수용액을 제조하였다: 제누비스코(등록상표) (허큘레스사) 0.55 g을 냉각, 탈염수 94.65 g에 넣었다. 이어서 강한 교반 하에 NaHCO3 4.8 g을 제조생성물에 첨가하였다. 용해를 완료한 후에, pH는 8 내지 8.4의 값으로 안정화시켰다. 1- A solution of carrageenan (Genubisco®, Hercules) (500,000 Da) was prepared as follows: 0.55 g of Genubisco® (Hercules) was added to 94.65 g of deionized water. Then 4.8 g of NaHCO 3 was added to the preparation under strong stirring. After complete dissolution, the pH was stabilized to a value of 8 to 8.4.
2- 가교제의 제조: 테레프탈산 디클로라이드 0.1 g을 에탄올 0.9 g에 용해시켰다. Preparation of the 2-crosslinker: 0.1 g of terephthalic acid dichloride was dissolved in 0.9 g of ethanol.
3- 카라게난 수용액의 가교: 교반 하에 2에서 제조한 용액을 1에서 제조한 수용액에 첨가하였다. 교반 하에 전체 용액을 60분 동안 두어, 한편의 활성화된 이산과 다른 한편의 다당류의 알콜 작용기 간의 중합을 초래하였다. 이 반응은 염기성 매질에서 촉진된다. 반응 후에, 가교된 카라게난 용액을 그대로 사용하거나 여과하여 불용성인 화합물을 제거할 수 있다. 텐싱 효과는 실시예 5에서 얻은 효과와 유사하였다. Crosslinking of the 3-carrageenan aqueous solution: The solution prepared in 2 was added to the aqueous solution prepared in 1 under stirring. The entire solution was left under stirring for 60 minutes, resulting in polymerization between the activated diacid on the one hand and the alcohol functional groups of the polysaccharide on the other. This reaction is promoted in basic medium. After the reaction, the crosslinked carrageenan solution can be used as is or filtered to remove insoluble compounds. The tensioning effect was similar to the effect obtained in Example 5.
점도의 측정 원리: 비가교된 다당류 수용액에 대한 가교된 다당류 수용액의 점도 측정을 행하였다. 사용한 점도계는 속도 50에서 사용되며 바늘침 04를 포함하는 브룩필드(Brookfield) RVTDV-II형 회전 장치였다. Principle of Measuring Viscosity: Viscosity measurement of crosslinked polysaccharide aqueous solution with respect to an uncrosslinked polysaccharide aqueous solution was performed. The viscometer used was a Brookfield RVTDV-II rotary device used at speed 50 and containing needle needle 04.
또한, 탄수화물의 중합은 이들의 분자량의 증가를 초래하고, 용해 매질에서 점도의 증가를 초래하였다. 이러한 점도의 증가를 검사하여 중합 정도를 측정할 수 있었다. In addition, the polymerization of carbohydrates resulted in an increase in their molecular weight and an increase in viscosity in the dissolution medium. The degree of polymerization could be measured by examining this increase in viscosity.
실시예 9b : 종래의 가수분해된 카라게난 수용액의 가교Example 9b Crosslinking of Conventional Hydrolyzed Carrageenan Aqueous Solutions
1- 다음과 같이 가수분해된 카라게난 (제누비스코(등록상표), 허큘레스사) 수용액을 제조하였다: 제누비스코(등록상표) (허큘레스사) 10 g을 0.1M HCl 용액 (0.1 몰/리터) 90 g에 넣었다. 중간 정도의 교반 하에 60℃에서 5시간 동안 가수 분해시키고, pH 8 내지 9 이하가 될 때까지 1M NaOH를 사용하여 중화시킴으로써 가수분해를 중지시켰다. 1- A hydrolyzed carrageenan (Genubisco®, Hercules) aqueous solution was prepared as follows: 10 g of Genubisco® (Hercules) was added with 0.1M HCl solution (0.1 mol / liter). ) Into 90 g. Hydrolysis was stopped by hydrolysis at 60 ° C. for 5 hours under moderate agitation and neutralized with 1 M NaOH until pH 8-9 or lower.
2- 가교제의 제조: 테레프탈산 디클로라이드 0.1 g을 에탄올 0.9 g에 용해시켰다. Preparation of the 2-crosslinker: 0.1 g of terephthalic acid dichloride was dissolved in 0.9 g of ethanol.
3- 카라게난 수용액의 가교: 교반 하에 2에서 제조한 용액을 1에서 제조한 수용액에 첨가하였다. 교반 하에 전체 용액을 60분 동안 두어, 한편의 활성화된 이산과 다른 한편의 다당류의 알콜 작용기 간의 중합을 초래하였다. 이 반응은 염기성 매질에서 촉진된다. 반응 후에, 가교된 카라게난 용액은 염을 제거하기 위해 초여과하고 이어서 불용성인 화합물을 제거하기 위해 여과하거나, 그대로 사용할 수 있다. 텐싱 효과는 상기 실시예에서 관찰된 효과 (특히 실시예 5의 생성물에 대해 얻은 효과)보다 훨씬 더 높았다.Crosslinking of the 3-carrageenan aqueous solution: The solution prepared in 2 was added to the aqueous solution prepared in 1 under stirring. The entire solution was left under stirring for 60 minutes, resulting in polymerization between the activated diacid on the one hand and the alcohol functional groups of the polysaccharide on the other. This reaction is promoted in basic medium. After the reaction, the crosslinked carrageenan solution can be ultrafiltered to remove salts and then filtered or used as is to remove insoluble compounds. The tensioning effect was much higher than the effect observed in the above example (especially the effect obtained for the product of Example 5).
실시예 10 : 라피노스 펜타히드레이트 (594 Da) 수용액의 가교Example 10 Crosslinking of Raffinose Pentahydrate (594 Da) Aqueous Solution
실시예 9의 단계 1 동안에, 10% 라피노스 용액을 제조하였다. 다른 단계 모두는 동일하였다. 텐싱 효과는 실시예 5에서 얻은 효과와 유사하지만, 매우 뚜렷한 연화 효과가 패널들에 의해 인지되었다. During step 1 of Example 9, a 10% raffinose solution was prepared. All other steps were identical. The tensioning effect is similar to that obtained in Example 5, but a very pronounced softening effect was recognized by the panels.
실시예 11 : 아카시아 검 수용액의 가교Example 11 Crosslinking of Acacia Gum Aqueous Solution
실시예 9의 단계 1 동안에, 5% 아카시아 검 (250,000 Da) 용액을 제조하였다. 다른 단계 모두는 동일하였다. 텐싱 효과는 실시예 5에서 얻은 효과보다 더 높았다. During step 1 of Example 9, a 5% acacia gum (250,000 Da) solution was prepared. All other steps were identical. The tensioning effect was higher than the effect obtained in Example 5.
실시예 12 : 다당류/폴리올 혼합물 수용액의 가교Example 12 Crosslinking of Aqueous Polysaccharide / Polyol Mixture
실시예 9의 단계 1 동안에, 글리세롤 (92 Da) (10%, w/w) 및 크산탄 (2%, w/w) 용액을 제조하였다. 다른 단계 모두는 동일하였다. 텐싱 효과는 실시예 5에서 얻은 효과와 유사하지만, 매우 뚜렷한 연화 효과가 패널들에 의해 인지되었다.During step 1 of Example 9, a solution of glycerol (92 Da) (10%, w / w) and xanthan (2%, w / w) was prepared. All other steps were identical. The tensioning effect is similar to that obtained in Example 5, but a very pronounced softening effect was recognized by the panels.
실시예 13 : 올리고당류/폴리올 혼합물 수용액의 가교Example 13 Crosslinking of Aqueous Oligosaccharide / Polyol Mixture
실시예 9의 단계 1 동안에, 만니톨 (182 Da) (10%, w/w) 및 이눌린 (약 5000 Da) (5%, w/w)의 용액을 제조하였다. 다른 단계 모두는 동일하였다. 텐싱 효과는 실시예 5에서 얻은 효과와 유사하지만, 매우 뚜렷한 연화 효과가 패널들에 의해 인지되었다.During step 1 of Example 9, a solution of mannitol (182 Da) (10%, w / w) and inulin (about 5000 Da) (5%, w / w) was prepared. All other steps were identical. The tensioning effect is similar to that obtained in Example 5, but a very pronounced softening effect was recognized by the panels.
실시예 14 : 수중유 에멀젼 형태의 화장료 또는 제약 제제에서 본 발명의 생성물의 사용Example 14 Use of the Product of the Invention in Cosmetic or Pharmaceutical Formulations in Oil-in-Water Emulsion
제제 14a : Formulation 14a :
제제 14b : Formulation 14b :
제제 14c : Formulation 14c :
실시예 15: 유중수 유형의 제제에서 본 발명의 생성물의 사용Example 15 Use of the Product of the Invention in Water-in-Water Type Formulations
실시예 16 : 샴푸 또는 샤워 젤 형태의 제제에서 본 발명의 생성물의 사용Example 16 Use of the Product of the Invention in Formulations in the Form of Shampoo or Shower Gel
실시예 17 : 립스틱 형태 및 다른 무수물 제품의 제제에서 본 발명의 생성물의 사용Example 17 Use of the Product of the Invention in the Form of Lipstick and Other Anhydride Products
실시예 18 : 수성 겔 (아이 크림(eye surround), 슬리머 등)의 제제에서 본 발명의 생성물의 사용Example 18 Use of the Product of the Invention in the Formulation of an Aqueous Gel (Eye Surround, Slimmer, etc.)
실시예 19 : 본 발명의 목적생성물을 함유하는 제조생성물의 미용 허용성의 평가Example 19 Evaluation of Cosmetic Acceptability of a Production Product Containing the Product of the Invention
토끼에 대해 시각 평가하고, 래트에 단독으로 경구 투여함으로써 비정상적 독성 부재를 연구하고, 기니아 피그에서 민감성을 연구함으로써, 0.5% 크산탄 겔 에 10%로 혼입된 실시예 2에 따라 수득된 화합물에 대한 독성학 시험을 행하였다.For the compounds obtained according to Example 2, which were visually evaluated in rabbits, studied for absence of abnormal toxicity by oral administration alone to rats, and studied sensitivity in guinea pigs, incorporated in 10% in 0.5% xanthan gel Toxicology tests were done.
토끼에 대한 일차 피부 자극 평가 :Primary skin irritation evaluation for rabbits:
"피부에 대한 급성 자극/부식 영향"의 연구와 관련된 OECD 지시문에 의해 제안된 방법에 따라서 3마리 토끼의 피부에 상기에 기재된 제조생성물을 희석시키지 않고 0.5 mL의 투여량으로 도포하였다.The skin of three rabbits was applied at a dose of 0.5 mL without dilution of the preparations described above according to the method proposed by the OECD directive relating to the study of “Acute irritation / corrosion effects on skin”.
1982년 2월 21일자로 프랑스 공화국의 약전 저널("JORF")에 반포된 1982년 2월 1일자 판결문에서 정의된 범주에 따라 생성물을 분류하였다.Products were classified according to the categories defined in the February 1, 1982 ruling, published on February 21, 1982, in the Journal of Pharmacopoeia of the French Republic ("JORF").
이들 시험 결과로서, 실시예 2에 따라서 수득된 화합물을 함유하는 제조생성물이 피부에 비-자극성인 것으로 분류되는 것으로 결론지었다.As a result of these tests, it was concluded that the preparation containing the compound obtained according to Example 2 was classified as non-irritating to the skin.
토끼에 대한 시각 자극 평가 :Visual stimulus evaluation for rabbits:
"눈에 대한 급성 자극/부식 영향"의 연구와 관련된 1987년 2월 24일의 OECD 제405호의 지시문에 의해 제안된 방법에 따라서 상기에 기재된 제조생성물을 순수한 형태로 한 배치에 0.1 mL의 속도로 한 방울씩 떨어뜨렸다.In accordance with the method proposed by the directive of OECD No. 405 of 24 February 1987 relating to the study of "Acute irritation / corrosion effects on the eyes", the preparations described above were carried out at a rate of 0.1 mL in batches in pure form. Drop by drop.
이들 시험 결과로서, 지시문 91/326 EEC의 의미에서 순수하거나 또는 희석시키지 않은 제조생성물은 눈에 비-자극성인 것으로 간주될 수 있다고 결론지었다.As a result of these tests, it was concluded that pure or undiluted preparations in the sense of Directive 91/326 EEC could be considered non-irritating to the eye.
래트에 단독으로 경구 투여함으로써 비정상적 독성의 부재에 대한 시험 :Test for absence of abnormal toxicity by oral administration alone to rats:
1987년 2월 24일의 OECD 제401호의 지시문으로부터 시사된 프로토콜에 따라서 5마리의 수컷 래트 및 5마리의 암컷 래트에, 상기 기재되고 미용료 생성물로 채택된 제조생성물을 한 배치에 신체 중량 kg당 5 g의 투여량으로 경구 투여하였다.Five male rats and five female rats, in accordance with the protocol suggested by the directive of OECD No. 401 of 24 February 1987, per kg body weight in a batch of the preparation product described above and employed as a cosmetic product. Oral administration was at a dose of 5 g.
LD0 및 LD50은 5,000 mg/Kg 초과인 것으로 밝혀졌다. 따라서 시험한 제조생성물은 섭취시 위험한 제조생성물 중 하나로 분류되지 않는다.LD0 and LD50 were found to be greater than 5,000 mg / Kg. Therefore, the tested production product is not classified as one of the dangerous production products when ingested.
기니아 피그에 대한 피부 민감성 평가 :Skin Sensitivity Assessment for Guinea Pigs:
OECD의 지시문 행 제406호에 따르는 프로토콜에 따라서 상기에 기재된 제조생성물에 대해 마그누손(Magnusson) 및 클리그만(Kligmann)에 의해 기재된 극한 시험을 행하였다.The extreme test described by Magnusson and Kligmann was conducted on the preparations described above according to the protocol according to OECD directive line 406.
상기 실시예에 기재된 제조생성물은 피부와 접촉시 비-민감성인 것으로 분류되었다.The preparations described in this example were classified as non-sensitive upon contact with skin.
비교하면, 상기 시험 프로토콜에 따라서, 실시예 1의 방법에 따라 가교된 시판 밀 단백질은 시험한 동물의 40%에 대해 민감성을 초래하였다. In comparison, according to the test protocol, commercial wheat proteins crosslinked according to the method of Example 1 resulted in sensitivity to 40% of the animals tested.
본 발명에 따르면, 임의의 확인가능한 알레르기 반응을 유발하지 않고도 사용자에 의해 인지가능한 방식으로 피부 표면에 텐싱 및(또는) 토닝 효과를 얻을 수 있고, 우수한 생체적합성, 완전한 생체분해성, 완전한 동화, 완전한 무해성을 갖는 출발 물질에 기재한 조성물 및 상기 조성물의 제조 방법을 제공할 수 있다.According to the present invention, it is possible to obtain a tensioning and / or toning effect on the skin surface in a manner recognizable by the user without causing any identifiable allergic reaction, with excellent biocompatibility, complete biodegradability, complete assimilation, complete harmlessness The composition described in the starting material having the properties and a method for producing the composition can be provided.
Claims (17)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0501674A FR2882366B1 (en) | 2005-02-18 | 2005-02-18 | RETICULATED CARBOHYDRATE POLYMER, IN PARTICULAR BASED ON POLYSACCHARIDES AND / OR POLYOLS |
FR0501674 | 2005-02-18 | ||
US11/174,414 US9133279B2 (en) | 2005-02-18 | 2005-07-01 | Cross-linked polymer of carbohydrate, notably based on polysaccharides, and/or on oligosaccharides and/or on polyols |
US11/174,414 | 2005-07-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060093072A true KR20060093072A (en) | 2006-08-23 |
KR101372646B1 KR101372646B1 (en) | 2014-03-10 |
Family
ID=36119848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060015801A KR101372646B1 (en) | 2005-02-18 | 2006-02-17 | Cross-Linked Polymers of Carbohydrates |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP5291863B2 (en) |
KR (1) | KR101372646B1 (en) |
DE (1) | DE102006007831C5 (en) |
ES (1) | ES2293816B2 (en) |
GB (1) | GB2423252B (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008144514A2 (en) * | 2007-05-17 | 2008-11-27 | Massachusetts Institute Of Technology | Polyol-based polymers |
US8455460B2 (en) * | 2007-08-31 | 2013-06-04 | Greentech | Cosmetic composition containing one or more compounds of the β-(1,3)-glucuronan or β-(1,3)-glucoglucuronan type |
JP4836087B2 (en) * | 2007-10-18 | 2011-12-14 | 株式会社ネオス | Selective fixing agent and selective fixing method of halogenated aromatic compound contained in medium |
EP2605746A2 (en) * | 2010-08-19 | 2013-06-26 | Merz Pharma GmbH & Co. KGaA | Filler composition comprising beta-glucans |
FR2997406B1 (en) * | 2012-10-25 | 2015-07-03 | Basf Beauty Care Solutions F | HYALURONATE AND GLUCOMANNAN POLYMER |
CN114409929B (en) * | 2022-02-07 | 2024-07-05 | 南京易亨制药有限公司 | Polymer hydrogel, preparation method and application thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2148951A (en) * | 1937-04-15 | 1939-02-28 | Du Pont | Organic starch derivatives and process |
US2461139A (en) * | 1945-01-08 | 1949-02-08 | Nat Starch Products Inc | Starch ester derivatives and method of making same |
NL302923A (en) * | 1963-04-06 | 1900-01-01 | ||
LU66959A1 (en) * | 1973-02-05 | 1974-09-25 | ||
DE2415556C3 (en) * | 1974-03-30 | 1982-09-09 | Henkel KGaA, 4000 Düsseldorf | Process for the production of high molecular weight substances treated with glyoxal |
US4152170A (en) * | 1975-06-18 | 1979-05-01 | Sumitomo Chemical Company, Ltd. | Cross-linked pullulan |
JPS51149883A (en) * | 1975-06-19 | 1976-12-23 | Sumitomo Chem Co Ltd | Hydrophilic gel |
US4226264A (en) * | 1975-09-02 | 1980-10-07 | Teepak, Inc. | Elastic amylose polymers |
JPS5366496A (en) * | 1976-11-22 | 1978-06-13 | Merck & Co Inc | Rapidly dispersible vegetable gum |
DE2908437A1 (en) * | 1979-03-05 | 1980-09-18 | Fresenius Chem Pharm Ind | NETWORKED HYDROXYAETHYL STARCH |
CA1238043A (en) * | 1983-12-15 | 1988-06-14 | Endre A. Balazs | Water insoluble preparations of hyaluronic acid and processes therefor |
US4716224A (en) * | 1984-05-04 | 1987-12-29 | Seikagaku Kogyo Co. Ltd. | Crosslinked hyaluronic acid and its use |
FR2688422A1 (en) * | 1992-03-11 | 1993-09-17 | Coletica | MICROCAPSULES WITH POLYSACCHARIDE WALLS CONTAINING PRIMARY ALCOHOL FUNCTIONS, AND COMPOSITIONS CONTAINING SAME. |
US5270459A (en) * | 1992-05-13 | 1993-12-14 | Shatzman Howard M | Method for producing dispersible xanthan gum products |
FR2701847B1 (en) | 1993-02-23 | 1995-05-05 | Coletica | Pharmaceutical and cosmetic compositions based on vegetable albumin, preparations containing such compositions and process for their preparation. |
US5840338A (en) * | 1994-07-18 | 1998-11-24 | Roos; Eric J. | Loading of biologically active solutes into polymer gels |
DE69526966T2 (en) * | 1994-12-20 | 2002-09-19 | L'oreal, Clichy Cedex | SKIN-STRENGTHING COMETIC COMPOSITION |
DE69733781T2 (en) * | 1996-03-22 | 2006-06-01 | National Starch And Chemical Investment Holding Corporation, New Castle | Hydroxypropylation stabilized waxy potato starch |
DE19627498A1 (en) * | 1996-07-08 | 1998-01-15 | Nat Starch Chem Invest | Starchy cleaning and care products |
FR2752843B1 (en) * | 1996-08-30 | 1998-10-16 | Sod Conseils Rech Applic | CROSSLINKED COPOLYMERS BASED ON POLYCARBOXYLIC POLYMERS AND THEIR USE AS SUPPORTS OF PHARMACEUTICAL COMPOSITIONS |
DE19643066C2 (en) | 1996-10-18 | 1999-07-01 | Henkel Kgaa | Collagen-free cosmetic preparations and processes for their production |
FR2766090B1 (en) * | 1997-07-15 | 1999-10-08 | Coletica | PARTICLES, IN PARTICULAR MICRO- OR NANOPARTICLES OF CROSS-LINKED VEGETAL PROTEINS, THEIR PREPARATION PROCESS AND COSMETIC, PHARMACEUTICAL OR FOOD COMPOSITIONS, CONTAINING |
FR2780901B1 (en) * | 1998-07-09 | 2000-09-29 | Coletica | PARTICLES, IN PARTICULAR MICRO- OR NANOPARTICLES OF CROSSLINKED MONOSACCHARIDES AND OLIGOSACCHARIDES, THEIR PREPARATION METHODS AND COSMETIC, PHARMACEUTICAL OR FOOD COMPOSITIONS CONTAINING THE SAME |
DE19920557B4 (en) * | 1999-05-05 | 2004-09-09 | Biotec Asa | Process for the production of collagen-free cosmetic preparations |
CN100340579C (en) * | 2001-08-07 | 2007-10-03 | 山口英子 | Hydrolysis polycondensation starch, process for producing the same and molded article made of hydrolysis polycondensation starch |
US20030108505A1 (en) * | 2001-08-17 | 2003-06-12 | Hongjie Cao | Use of xanthan gum as a hair fixative |
FR2832157B1 (en) | 2001-11-09 | 2004-06-04 | Silab Sa | PROCESS FOR THE PREPARATION OF AN ACTIVE INGREDIENT BASED ON POLYMERIZED PROTEINS, ACTIVE INGREDIENT AND COMPOSITION WITH A SMOOTHING EFFECT, ANTI-WRINKLES AND IMMEDIATE SKIN TENSIONER |
US20030099691A1 (en) * | 2001-11-16 | 2003-05-29 | Susan Lydzinski | Films containing starch |
US20030094104A1 (en) * | 2001-11-21 | 2003-05-22 | Roger Jeffcoat | Process tolerant low amylose tapioca distarch adipates |
JP2004217590A (en) * | 2003-01-16 | 2004-08-05 | Unitika Ltd | Cosmetic composition |
JP4057927B2 (en) * | 2003-02-05 | 2008-03-05 | 英子 山口 | Starch hydrolyzed saccharide and its condensation polymer |
FR2861734B1 (en) * | 2003-04-10 | 2006-04-14 | Corneal Ind | CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED |
-
2006
- 2006-02-10 GB GB0602683A patent/GB2423252B/en not_active Expired - Fee Related
- 2006-02-16 ES ES200600364A patent/ES2293816B2/en active Active
- 2006-02-17 JP JP2006041154A patent/JP5291863B2/en not_active Expired - Fee Related
- 2006-02-17 KR KR1020060015801A patent/KR101372646B1/en active IP Right Grant
- 2006-02-17 DE DE102006007831.4A patent/DE102006007831C5/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
GB2423252A (en) | 2006-08-23 |
ES2293816A1 (en) | 2008-03-16 |
JP5291863B2 (en) | 2013-09-18 |
DE102006007831C5 (en) | 2018-05-24 |
GB2423252B (en) | 2007-10-17 |
DE102006007831B4 (en) | 2009-08-20 |
GB0602683D0 (en) | 2006-03-22 |
KR101372646B1 (en) | 2014-03-10 |
ES2293816B2 (en) | 2010-03-11 |
DE102006007831A1 (en) | 2006-10-12 |
JP2006225392A (en) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9133279B2 (en) | Cross-linked polymer of carbohydrate, notably based on polysaccharides, and/or on oligosaccharides and/or on polyols | |
JP6377020B2 (en) | Carboxymethyl group-containing modified hyaluronic acid and / or salt thereof, and cosmetics, food compositions and pharmaceutical compositions containing the same | |
JP5241708B2 (en) | Cationized hyaluronic acid and / or salt thereof, method for producing the same, and hair modifying agent, cuticle restorative agent, skin modifying agent and cosmetics using the same | |
KR101372646B1 (en) | Cross-Linked Polymers of Carbohydrates | |
JP4845071B2 (en) | Modified hyaluronic acid and / or salt thereof, process for producing the same and cosmetics containing the same | |
JP5824599B1 (en) | Method for producing hyaluronic acid and / or salt thereof | |
JP2002521054A (en) | Carrageenan compositions and methods for their manufacture | |
AU2008337407A1 (en) | Crosslinked hyaluronic acid in emulsion | |
JP2008285421A (en) | Hair modification penetrant and cosmetic for hair using the same | |
WO2015053282A1 (en) | Crosslinked product of carboxymethyl-group-containing modified hyaluronic acid and/or salt thereof, and method for producing same | |
JP5814181B2 (en) | Skin barrier function improver | |
JP5734536B1 (en) | Carboxymethyl group-containing modified hyaluronic acid and / or a salt thereof and a method for producing the same | |
JPH045489B2 (en) | ||
JP2004217590A (en) | Cosmetic composition | |
JP3878629B2 (en) | COMPOSITE AQUEOUS GEL, PROCESS FOR PRODUCING THE SAME, GELATED FORMULATION CONTAINING THE COMPOSITE AQUEOUS GEL, EXTERNAL SKIN, AND COSMETIC | |
JP2018140959A (en) | Detergent composition containing hydrophobic starch and cosmetics containing the same | |
JP2019108298A (en) | Composition in format of o/w emulsion including fermentation product of grain and hectorite | |
JP6599673B2 (en) | Hyaluronic acid and / or salt thereof, and foods, cosmetics, and pharmaceuticals containing the hyaluronic acid and / or salt thereof | |
JP2016199515A (en) | Emulsion cosmetic | |
KR20070121027A (en) | Cosmetic delivery system and process for manufacture thereof | |
JP2016199516A (en) | Gel-like cosmetic | |
JP2023092506A (en) | Oil-in-water type emulsion composition and method for producing the same | |
JP5849017B2 (en) | Cosmetics and method for producing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170306 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20190219 Year of fee payment: 6 |